Does ovarian suspension during laparoscopic surgery for endometriosis reduce postoperative adhesions? A randomised controlled trial by Hoo, WL
Does ovarian suspension during 
laparoscopic surgery for 
endometriosis reduce postoperative 
adhesions? 
A randomised controlled trial 
 
Wee-Liak Hoo 
 
The Gynaecology Diagnostic and Outpatient Treatment Unit, Department 
of Obstetrics and Gynaecology, Elizabeth Garrett Anderson Wing,  
University College Hospital, Grafton Way, London WC1H 
 
Thesis submitted for the degree of MD(Res),  
University College London 
 
March 2017 
  
  2 
Declaration 
I, Wee-Liak Hoo, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has 
been indicated in the thesis. I was personally involved in the design of the 
study, applications for ethical approval, recruitment of participants, ultrasound 
scan assessment and collection of data. None of the data presented is a part of 
any other thesis. All patients gave informed consent prior to participation in the 
study. 
 
 
 
 
 
 
_____________  
Wee-Liak Hoo  
  
  3 
Abstract 
In this thesis, I have explored complex pathology of endometriosis, described 
current management strategies and highlighted the common problem of 
postoperative pelvic adhesions, often associated with the surgical treatment of 
this condition. Intra-operative suspension of the ovaries to the anterior 
abdominal wall is a simple method used to facilitate ovarian retraction during 
surgery.  
We found in an observational (pilot) study that the prevalence of ovarian 
adhesions for each ovary was 56.3% after laparoscopic surgery for severe 
pelvic endometriosis. A prospective double-blind cross-over comparison 
randomised controlled trial (RCT) was completed to assess the effect of 
temporary ovarian suspension following laparoscopic surgery for severe pelvic 
endometriosis on the prevalence of postoperative ovarian adhesions. Suitable 
women were randomised to unilateral ovarian suspension for 36 to 48 hours in 
the postoperative period. A transvaginal ultrasound scan was performed three 
months after surgery to assess for the prevalence of ovarian adhesions. Our 
RCT concluded that there was no significant difference (P = 0.23) in the 
prevalence of postoperative ovarian adhesions between the suspended (20/52) 
and unsuspended (27/52) side (38.5 versus 51.9%) [odds ratio 0.56 (95% 
confidence interval 0.22–1.35)]. 
Using the ovarian suspension RCT as a basis, I have described the detailed 
journey of an RCT from its conception, protocol design, pilot study, trial 
management, analysis to publication of results. The rationale for our study 
design and methodology was discussed. Statistical considerations were made 
from the outset, which led to a pilot study. Issues surrounding the 
implementation of our trial including ethical approval, recruitment, consent, 
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randomisation and details of data management were outlined. Finally, statistical 
analysis, conclusions, limitations and suggestions for future research were 
made. 
Current Controlled Trials: ISRCTN24242218 
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Chapter 1 – History, Epidemiology and Characterisation 
Endometriosis is one of the most common benign gynaecological conditions. It 
is classically defined as the presence of endometrial glands and stroma in 
ectopic sites outside the uterus. It is variable in both its clinical and surgical 
manifestations, often with poor correlation between the two. Despite numerous 
papers on endometriosis, its aetiology and pathogenesis remain elusive and 
there appears to be a polygenic and multifactorial pattern of inheritance.  
1.1 History of endometriosis 
The history of medicine is full of controversies and certainly the origin of 
endometriosis is confounded by the fact that for some time, endometriosis and 
adenomyosis were considered to be the same condition – ‘adenomyoma’. It 
was not until the mid-1920s that the two conditions were finally separated.  
Knapp1 who performed a historical review of endometriosis, believed that the 
first descriptions could be found in theses and dissertations published from as 
early as 1690. Daniel Shroen, a German physician, described in his book, 
Disputatio Inauguralis Medica de Ulceribus Ulceri, ulcers that in their primary 
form were distributed throughout the ‘stomach’ (the peritoneum) and were 
located prominently in the bladder, the intestines, the broad ligament and the 
outside of the uterus and cervix.  
Carl Rokitansky, a German pathologist, in 1860 was the first to provide a 
detailed pathological description of endometriosis2. Rokitansky identified the 
presence of heterotopic endometrial tissue as three different phenotypes: 
myometrial, endometrial cavity (a polyp) and ovarian3. However, he considered 
these phenotypes neoplastic and labelled them as ‘sarcomas’. Breus used the 
term “chocolate cyst” for the first time in 1894. 
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In 1896, Thomas Cullen described for the first time, the morphology and clinical 
appearance of endometriosis. He described ‘adenomyoma’ of the round 
ligaments, which he asserted was tissue of Mullerian origin4. Further ideas on 
the pathogenesis were put forward and developed during the early 20th century.  
It is perhaps customary to describe John A. Sampson as the originator of 
endometriosis5. In 1927, he formulated a new concept in the article titled 
“Peritoneal Endometriosis due to the Menstrual Dissemination of Endometrial 
Tissue into the Peritoneal Cavity6.” His description of peritoneal endometrium 
and ovarian endometrioma provided the first theory on the pathogenesis of the 
disease6,7. The hypotheses for the origin of endometriosis from this article 
dominated the criteria and the scientific literature on endometriosis for the next 
80 years.  
1.2 Epidemiology 
The prevalence of endometriosis in the general population is unknown and 
varies according to the population studied. It can affect about 6%–10% of 
women in the reproductive age8 and has a prevalence rate as high as 35%–
50% in women experiencing pain or infertility9,10.  
The incidence of endometriosis is increased with uterine anomalies resulting in 
obstruction of menstrual outflow, in-utero exposure to diethylstilbestrol, a low 
birth weight, in women with family history of endometriosis and those with 
naturally red hair11–13. Endometriosis is also associated with prolonged 
exposure to endogenous oestrogen (early menarche, late menopause or 
obesity), consumption of red meat and unsaturated fats. Whereas, prolonged 
lactation, multiple pregnancies and eating fruits, green vegetables, and n−3 
long-chain fatty acids are protective14. Endometriosis is also associated with an 
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increased risks of autoimmune diseases and ovarian endometrioid or clear-cell 
cancers15.  
1.3 Characterisation  
Although considered a progressive disease, endometriosis can remain static 
and even regress without treatment16. The extent of endometriosis varies, but 
three well recognised forms of endometriosis have been described17: 
1. Peritoneal endometriosis corresponds to minimal or mild endometriosis, 
has multiple appearances. The classic lesion has a puckered, blue–black 
powder-burn appearance. Early lesions however, may appear as 
papular, vesicular or glandular, haemorrhagic or flame-like lesions. Neo-
angiogenesis and adhesion formation are typical features of the early 
active implant. Red lesions are believed to be early and very active 
lesions, black lesions as advanced and active lesions, whilst white 
lesions are healed or inactive lesions18. 
2. Ovarian endometriosis is characterized superficial ovarian implants or 
endometriotic cysts (endometriomas). These are often found adherent to 
the posterior aspects of the broad ligament. Most endometriomas are 
pseudocysts formed by invagination of the ovarian cortex, which is 
sealed off by adhesions. The site of invagination is characterized by 
fibrosis, retraction of the cortex, islands of glandular endometriotic tissue 
and organized blood clots. The pseudocysts are completely or partially 
lined by a thin endometrial-like mucosa consisting of a surface epithelium 
and highly vascularized stroma19. Endometriomas are more commonly 
found on the left ovary20.  
3. Deep infiltrating endometriosis (DIE) is predominantly glandular and 
stromal tissue surrounded by hyperplastic smooth muscle cells. DIE 
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nodules extend >5 mm beneath the peritoneum and typically involve the 
uterosacral ligaments, vagina, bowel, bladder or ureters. The depth of 
infiltration is related to the severity of symptoms21–23. The inflammatory 
reaction causes overgrowth and retraction simulating a malignant 
invasion, however endometriotic infiltrations are not destructive, does not 
invade fat tissue and does not breach the basal membrane of the 
bowel19. 
1.4 Location  
Endometriotic implants have been found almost anywhere in the female body. 
More commonly, they occur on the pelvic peritoneum, the ovaries, pouch of 
Douglas (POD), uterosacral ligament, uterovesical pouch, serosal surface of the 
uterus, fallopian tubes and round ligament. Endometriosis has also been found 
in the perineum, along episiotomies scar or in Bartholin glands. Occasionally, 
the implants can be found at more distant sites, including lung, liver, pleura and 
pericardium with consequent variations in presenting symptoms.  
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Chapter 2 – Pathophysiology  
The exact aetiology and pathogenesis of endometriosis remains unclear and its 
variable morphology appears to represent a continuum of individual 
presentations and progressions. Many theories have been postulated but a 
unifying theory regarding the origin of endometriosis remains elusive.  
2.1 Endometriosis Theories 
1. Vascular and lymphatic metastasis (Halban’s theory) 
The theory of benign metastasis suggests that ectopic endometrial implants 
occur via vascular or lymphatic spread of viable endometrial cells24,25. This 
theory could explain the rare occurrences of endometriotic lesions found in 
extra pelvic sites such as the brain, bone and lungs17.  
2. Coelomic metaplasia (Meyer’s theory) and induction theory  
Coelomic metaplasia is based on the fact that cells from the peritoneum, the 
ovarian surface and endometrium arise from a common embryological 
precursor, the coelomic cell. It assumes that a transformation occurs of 
normal peritoneal tissue into ectopic endometrial tissue26,27.  
A closely related induction theory holds that an endogenous inductive 
stimulus, such as a hormonal or immunologic factor, promotes the 
differentiation of cells in the peritoneal lining to endometrial cells26.  
Agents responsible for such transformation remain poorly defined and 
investigators have not been able to show that peritoneal cells can be 
differentiated experimentally into endometrial cell types.  
3. Müllerianosis 
The theory of embryonic Müllerian rests or müllerianosis, proposes that 
residual cells from the embryologic Müllerian duct migration maintain the 
capacity to develop into endometriotic lesions under the influence of 
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oestrogen28. This theory find support in epidemiological studies reporting a 
twofold-increase in the risk of developing endometriosis in women exposed 
to diethylstilbestrol in utero11. 
4. Retrograde menstruation and implantation theory (Sampson’s theory) 
Sampson’s theory from the 1920s on retrograde or reflux menstruation 
model has been the most widely accepted theory explaining the 
development of endometriosis and is supported by multiple lines of 
evidence6. This theory suggests that the origin of endometriosis is a 
consequence of the reflux of endometrial fragments through the fallopian 
tubes during menstruation, with subsequent implantation and growth on or 
into the peritoneum and ovary. 
Sampson based his theory on observations of menstrual blood exiting the 
tubal ostea in menstruating women during pelvic surgery. Reflux 
menstruation occurs in up to 90% of women with patent fallopian tubes 
undergoing laparoscopy during menstruation29. Further support for this 
theory can be found in cases of uterine anomalies where outflow obstruction 
increases the prevalence of endometriosis13. A higher prevalence of 
endometriosis is also seen in cases of compromised antegrade 
menstruation such as septate uteri and cervical stenosis30,31. Menstruations 
are often longer and heavier in women with endometriosis32. The anatomical 
distribution of endometriotic lesions also supports the retrograde 
menstruation theory with the tendency of lesions to implant in the pouch of 
Douglas, the most dependent portion of the peritoneal cavity33.  
Overall, endometriosis is likely the result of a complex interplay of endometrial 
tissue, the peritoneal environment and the peritoneal lining. When the 
peritoneal environment cannot remove endometrial tissue in time, the 
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endometrial tissue will adhere to the peritoneal lining. The innate capacity of the 
endometrial tissue to invade and acquire a blood supply contributes to the 
implantation process. After implantation, local production of oestrogens as a 
result of the expression of aromatase provides a local, continuous, ovary-
independent growth stimulus. Changes in the physiology of the endometrium, 
increasing amounts of retrograde menstruation and/or changes in the contents 
of the peritoneal fluid, can disturb the defence mechanism against the 
endometrial tissue and further promote implantation. If endometrial tissue is to 
implant in the peritoneum, it must be able to adhere to the peritoneal surface, 
invade the basement membrane and extracellular matrix, acquire a blood 
supply and survive. 
Immunological and inflammatory factors are likely to contribute to the 
progression from retrograde menstruation to endometriosis. Two theories have 
been suggested, 1) an intrinsic anomaly of eutopic endometrium that develops 
resistance from elimination by peritoneal immune cells and 2) a consequence of 
an altered function of peritoneal macrophages and natural killer (NK) cells that 
are unable to eliminate the endometriotic implants34. The relationship between 
the two theories is not clear, although they are likely to be interdependent. The 
peritoneal environment may induce alterations in the ectopic endometrial tissue 
in those with a genetic predisposition, thus facilitating implantation and invasion. 
However, an excess of refluxed endometrium may induce a pro-inflammatory 
and hormonal environment that produces endometrial changes and favours the 
metaplasia of coelomic epithelium, which is already altered by peritoneal 
inflammation. Some molecular alterations described in endometriosis are 
related to disorders of angiogenesis and dysregulation in the apoptosis of 
immune and ectopic endometrial cells. The serum and peritoneal fluid of infertile 
  23 
women with endometriosis appears to have higher levels of IL-6, IL-8, and NK 
cells35. 
Peritoneal endometriotic lesions occur so frequently that they are sometimes 
considered a physiological and temporal process34. Second-look laparoscopy 
has revealed that spontaneous resolution of peritoneal endometriosis occurred 
in 42% of affected patients36. Hormonal treatments often result in a significant 
reduction of peritoneal endometriotic lesions, although they subsequently 
reappeared a few months after the menstrual cycle resumed37. Some peritoneal 
endometriotic lesions progress to mature “black” lesions or white scar lesions17. 
Other implants grow and develop into dense adhesions, endometriomas and 
DIE. One explanation is that endometriosis is a heterogeneous condition with 
peritoneal, deep infiltrating and ovarian implants being manifestations of 
different disease processes17. They proposed retrograde menstruation for 
peritoneal endometriosis, müllerianosis for rectovaginal endometriotic nodules 
and metaplasia for ovarian endometriotic lesions. Intrinsic to these theories are 
stimulating factors and genetic susceptibilities whose roles are only now 
beginning to be delineated, although they are insufficiently established. The 
developmental timing of action of these factors and their roles in influencing 
other systems that predispose to endometriosis (endocrine, immune, 
stem/progenitor cells, epigenetic modifications) must be considered in the 
context of genetic background38.  
The immunological response triggered to eliminate these implants, could have 
detrimental effects on fertility. Individuals with genetic predisposition and 
immunotolerance to endometrial antigens (decreased NK activity and T-cell 
anergy) could lead to the progression of endometriosis. This progression 
presents with infiltrating nodular and cystic lesions with characteristic clinical 
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manifestations with advancing disease. Infertility may be caused by mechanical 
factors, such as adhesions, tubal distortion, or altered oocyte quality39,40. In 
immunocompetent women, the disease does not progress and a temporary 
infertility similar to that seen in women with unexplained subclinical infertility 
may occur.  
Tariverdian et al.41 proposed the concept of endometrial dissemination as a 
result of neuroendocrine-immune disequilibrium in response to stress caused by 
cardinal clinical symptoms of endometriosis. This induces a vicious cycle of 
peritoneal inflammation, angiogenesis resulting in pain and infertility.  
The role of steroid hormones in the progression of endometriosis has been 
highlighted. Normal eutopic endometrium expresses the isoforms A (PR-A) and 
B (PR-B) of progesterone receptors; in the secretory phase, progesterone 
indirectly induces the 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD-2), 
which converts oestradiol to oestrone, leading to the apoptosis of endometrial 
cells. In ectopic endometrium, low levels of PR-A, no PR-B, and no 17β-HSD-2 
are detectable. As a consequence, oestradiol accumulates and likely induces 
the proliferation of endometrial tissue. Moreover, the enzyme aromatase that is 
present in ectopic tissue creates oestrone, which is further converted to 
oestradiol by 17β-HSD type 1, thus contributing to the accumulation of 
oestradiol. Ectopic endometrium has also been found to express oestrogen 
receptors, progesterone receptors and occasionally P450 aromatase42,43. This 
enzymatic activity results in the conversion of circulating androstenedione into 
oestrone in tissue, which is an oestrogen that further promotes the growth of 
endometriotic implants44,45. This explains the use of aromatase inhibitors in 
combination with Gonadotropin-releasing hormone (GnRH) analogues or oral 
contraceptives for the treatment of endometriosis46,47. 
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A genetic predisposition for endometriosis was illustrated by Simpson et al.48 
who suggested a polygenic or multifactorial inheritance. They reported a 5 – 8% 
observed risk of endometriosis in first-degree relatives with endometriosis. 
Severe endometriosis was also most likely when a ﬁrst-degree relative is 
affected (61% vs. 24%). Studies found genetic associations with endometriosis 
for single-nucleotide polymorphisms at different chromosome loci in Caucasian 
and Japanese populations49,50. Genes located in the 1p36 region and 7p15.2 
have been associated with endometriosis51,52.  
There is also increasing concern about chemical pollutants mimicking hormonal 
function, so-called endocrine-disrupting compounds53. A substantial number of 
environmental pollutants, such as polychlorinated biphenyls, dioxins, polycyclic 
aromatic hydrocarbons, phthalates, bisphenol A, pesticides, alkylphenols, and 
heavy metals have been shown to disrupt endocrine function54–57. Their 
structural similarity to endogenous hormones causes them to interact with 
hormone transport proteins or potentially disrupt hormone metabolic pathways, 
leading to development of endometriosis. 
2.2 Mechanisms of Pain in Endometriosis 
The cause of endometriosis-associated pain is unknown. It has been suggested 
that peritoneal inflammation as a result of growth factors and cytokines 
production by activated macrophages, adhesion formation may be 
responsible58. The active bleeding or direct invasion of pelvic nerves by 
endometriotic implants has also been suggested23. The neural irritation or 
invasion hypothesis is increasingly popular. Tender nodularity in the pouch of 
Douglas and uterosacral ligaments has 85% sensitivity and 50% specificity for 
the diagnosis of DIE59. The intensity of pain associated with infiltrative disease 
has been correlated with the depth of penetration of the lesion and the most 
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severe pain is seen when the disease extends 6 mm or more below the 
peritoneal surface58. These women are more likely to have deep dyspareunia, 
severe dysmenorrhea and dyschezia (painful or difficulty in defecating). 
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Chapter 3 – Signs, Symptoms, Diagnosis and Staging 
3.1 Signs & Symptoms of Endometriosis  
Endometriosis is frequently associated with dysmenorrhoea, chronic pelvic pain, 
deep dyspareunia, dyschezia and infertility. The intensity of symptom will range 
from mild to severe, but the relationship between pain intensity and 
endometriosis severity is not clear. Ballard et al.60 found that 83% of women 
with endometriosis reported one or more of these symptoms when compared 
with just 29% of controls. Dyschezia during menstruation and deep dyspareunia 
have been found to be stronger predictors of DIE (sensitivity 74.5%, specificity 
68.7%, positive likelihood ratio (LR+) of 2.4 and negative likelihood ratio (LR-) of 
0.4)61. There is often no clear relationship between the staging of disease and 
symptom severity, although, many studies have reported an increase in pain 
symptoms with increasing depth of DIE62,63.  
Pelvic pain can occur unpredictably throughout the menstrual cycle or 
continuously. It is often described as a dull, throbbing or sharp pain 
exacerbated by physical activity16. Bladder and bowel endometriosis symptoms 
are typically cyclical.  
Despite the growing awareness of endometriosis symptoms, there are often 
significant delays between the onset of symptoms to definitive diagnosis, with a 
mean latency of 6.7 years reported in Norway, 8 years in the United Kingdom 
and 11.7 year in the USA64. One explanation for this delay is the significant 
overlap in symptoms with other conditions such as pelvic inflammatory disease, 
pelvic adhesions, irritable bowel syndrome, inflammatory bowel disease, 
interstitial cystitis and depression. Indeed, when the records of general 
practitioners were reviewed, women with endometriosis were 3.5 times more 
likely to have had a diagnosis of irritable bowel syndrome and 6.4 times more 
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likely to have a diagnosis of pelvic inflammatory disease when compared with 
women without endometriosis65. Other than misdiagnosis, factors contributing to 
a diagnostic delay include the use of contraception causing hormonal 
suppression of symptoms, stigmata towards menstruation resulting in 
normalisation of symptoms, higher BMI and healthcare funding66,67.  
3.2 Diagnosis 
The diagnosis of endometriosis is first suspected based on the history, then 
substantiated by physical examination and imaging techniques and is finally 
confirmed by histological examination of specimens collected during 
laparoscopy.  
When considering laparoscopy to diagnose and treat endometriosis, a balance 
must be found between the need to avoid the very long diagnostic delays 
currently experienced, the likelihood of treatment benefits against the cost and 
risk of laparoscopy. It remains questionable whether the early detection and 
staging of endometriosis is necessary. As previously discussed, early 
progression and regression is unpredictable. The reality is that there is currently 
no cure for endometriosis and it is difficult to justify a diagnostic laparoscopy for 
minimal or mild endometriosis only. Moreover, even if peritoneal disease is 
found it might not be the cause of pain. One could argue that empirical 
treatment can be started without a definitive diagnosis68. This may be 
appropriate in young adolescents or in women that decide not to have a 
laparoscopy. If medical treatment relieves pain, many women may not be 
interested in whether or not their pain symptoms were due to peritoneal 
endometriosis69.  
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3.2.1 Clinical Examination 
Routine vaginal examination alone is often insufficient to make a diagnosis of 
endometriosis70. However, DIE or nodules can sometimes be visualised or 
palpated in the posterior fornix of the vagina wall71. These appear as dark blue 
lesions, which are often dense, painful and can increase in size during 
menstruation69,71.  
3.2.2 Laparoscopy  
A definitive diagnosis usually requires the visual inspection of the pelvis at 
laparoscopy. Diagnosis is ideally accompanied by histological confirmation of 
both typical and atypical lesions, but a negative histology does not exclude the 
diagnosis68. Although histopathology is not routinely required, selected biopsies 
are recommended for atypical lesions to exclude malignancy and differentiate 
from other benign lesions including haemangioma, epithelial inclusions, foreign 
body reaction (contrast or suture material), inflammatory cystic inclusions, 
schistosomiasis (gelatinous deposits), Psammoma body reaction, adrenal rest, 
Walthard's cell rest, ovarian cancer, splenosis, endosalpingiosis, ectopic 
pregnancy and secondary trophoblast implantation18. 
The indication for laparoscopy needs to be individualised and should include 
the woman’s choice to have a definitive diagnosis, infertility and/or symptoms 
and signs of severe disease, such as ovarian endometriomas or DIE or on-
going pain symptoms. 
A negative diagnostic laparoscopy, where no endometriosis is identified, seems 
to be highly accurate for excluding endometriosis and is therefore useful to a 
clinician in making management decisions72. However, the experience, skill and 
knowledge of the surgeon determine whether endometriosis will be diagnosed if 
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present. DIE and vaginal endometriosis can be easily missed if the patient has 
not been thoroughly examined, preferably under anaesthesia.  
A good quality laparoscopy should include systematic examination of 1) the 
uterus and adnexa, 2) the peritoneum of ovarian fossae, vesico-uterine fold, 
pouch of Douglas and pararectal spaces, 3) the rectum and sigmoid, 4) the 
appendix and caecum and 5) the diaphragm. Under general anaesthesia, there 
should also be a speculum examination and palpation of the vagina and cervix, 
to check for 'buried' nodules.  
3.2.3 Biomarkers  
A diagnostic test without the need for surgery would reduce associated surgical 
risks and increase accessibility to a diagnostic test. Considerable effort has 
been invested in searching for less-invasive techniques to diagnose 
endometriosis. A biomarker is a measurable “biologic marker” that correlates 
with a specific outcome or state of the disease73. Cancer antigen 125 (CA-125), 
cytokines and angiogenic growth factors all show altered levels in the peripheral 
blood of women with endometriosis when compared to controls, however their 
potential as a diagnostic measure for endometriosis, either alone or in 
combination, has been disappointing74–77.  
Evidence suggesting a significant difference between the eutopic endometrium 
from women with and without endometriosis has led to proteomic studies 
searching for a diagnostic test based on the analysis of an endometrial 
biopsy78,79.   
Circulating microRNAs are also being evaluated as a novel biomarker. As a 
multifactorial and polygenic disease, the dysregulation of miRNA expression 
has been implicated in endometriosis80. MicroRNAs are a class of regulatory 
molecules with the ability to control gene expression at the post-transcriptional 
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level through degradation, repression, and silencing, which could be used as 
biomarkers or therapeutic tools in endometriosis81.  
3.2.4 Imaging  
A non-invasive, preoperative diagnosis of endometriosis has been made 
possible by recent advances in imaging modalities such as ultrasound and 
magnetic resonance imaging (MRI)82.  
With regards to endometriomas, transvaginal ultrasound (TVS), with or without 
the use of Doppler, has been shown to be a highly sensitive tool and is far 
superior to routine clinical examination alone. Moore et al.83 concluded in a 
systematic review that TVS imaging of ovarian endometriomas had a diagnostic 
sensitivity of 64 to 89%, specificity 89 to 100%, LR+ 7.6 to 29.8 and LR− of 0.1 
to 0.4.  
Currently, it is not possible to detect peritoneal endometriosis on TVS. MRI was 
found to only have a sensitivity of 69%, specificity of 75%, LR+ 2.76, and LR− 
0.4184. Unfortunately, these LRs are too low to justify the routine use of MRI to 
diagnose peritoneal disease.  
Physical examination has limited value for assessing the extent of DIE85. 
Recent studies have shown TVS, rectal endoscopic sonography (RES) and MRI 
to be useful in the diagnosis of non-ovarian endometriosis, such as uterosacral 
ligament, rectosigmoid colon, rectovaginal space and the pouch of Douglas. 
Bazot et al.71 found that MRI was more accurate than TVS or RES in the 
diagnosis of uterosacral ligament and vaginal endometriosis, although, TVS 
appeared to be most accurate in diagnosing bowel endometriosis. The 
sensitivity, LR+ and LR- values of MRI, TVS and RES were respectively, 
84.4%, 7.59 and 0.18, and 78.3%, 2.34 and 0.32, and 48.2%, 0.86 and 1.16 for 
uterosacral ligament endometriosis; 80%, 5.51 and 0.23, 46.7%, 9.64 and 0.56, 
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6.7%, - and 0.93 for vaginal endometriosis, and 87.3%, 12.66 and 0.14, 93.6%, 
- and 0.06, 88.9%, 12.89 and 0.12. In a systematic review of the diagnostic 
accuracy of TVS for diagnosing DIE with bowel involvement, Hudelist et al.86 
reported a sensitivity of 91%, specificity 98%, LR+ 30.36, LR− 0.09, PPV 98% 
and NPV 95%.  
It has been suggested that a limitation of TVS is its inability to determine the 
exact distance of the rectal lesions from the anal margin or to evaluate the 
depth of rectal wall involvement. RES has been suggested in these cases 
where colorectal involvement is suspected if necessary87.  
TVS is easily accessible, cost and time effective. It is not surprising that it has 
become the first-line investigation in the diagnosis of endometriosis. However, it 
should be noted that this level of ultrasonography is operator dependent and 
requires a very experienced operator. In the clinical setting, excluding DIE is of 
critical importance since extensive bowel involvement warrants an 
interdisciplinary approach and may necessitate a referral to a tertiary centre. 
Accurate preoperative staging could facilitate more effective triaging of women 
for a more appropriate level of surgical care. Zanardi et al.88 found a high 
concordance between MRI and laparoscopy for staging of pelvic endometriosis 
according to the revised American Society of Reproductive Medicine (ASRM) 
classification (kappa = 0.913). However, they also found MRI to have a 
suboptimal depiction of adhesions and complete obliteration of the pouch of 
Douglas. Holland et al.89 showed that TVS was a useful test for assessing the 
severity of pelvic endometriosis and was particularly accurate in detecting 
severe disease, sensitivity 0.85, specificity 0.98 and LR+ was 43.5, and LR− 
was 0.15.  
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3.3 Staging of Endometriosis 
One of the major challenges of making a diagnosis in women with suspected 
endometriosis is to assess the extent of the disease and its functional 
consequences for the pelvic or extra-pelvic organs. Although several 
classification systems have been suggested for endometriosis90,91, the most 
widely used staging system for the extent of endometriosis is the revised ASRM 
classification92 (Figure 1 and 2).  
The ASRM classification system was established to predict fertility outcomes 
and determine disease burden and management. The extent of endometriosis 
is graded from stage I, indicating minimal disease, to stage IV, indicating severe 
disease on the basis of the type, location, appearance, size and depth of 
peritoneal or ovarian implants and adhesions visualised during laparoscopy and 
allow uniform documentation of the extent of disease. However, the staging of 
the disease does not correlate well with the severity of pain symptoms or 
response to therapies or future infertility or predict disease progression93,94. 
There was also limited reproducibility noted with the ASRM classification 
system, with the greatest inconsistency noted for endometriosis of the ovary 
and pouch of Douglas obliteration93. An awareness of the subtle appearances 
of peritoneal endometriosis also increases the likelihood of observational error, 
which affects staging95. Other factors, which can affect staging of 
endometriosis, include spontaneous or hormone-induced amenorrhoea, 
previous pelvic surgery and pelvic inflammatory disease. 
Other classifications of endometriosis have been suggested, but there is 
currently no validated system that meets clinical needs96. 
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Figure 1 The revised American Society of Reproductive Medicine (ASRM) 
classification of endometriosis92 
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Figure 2 Examples of ASRM classification of endometriosis disease97 
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Chapter 4 – Medical Therapies  
4.1 Introduction  
The precise pathogenesis of endometriosis remains unclear and it is assumed 
that these deposits of ectopic endometrium are responsible for the symptoms of 
endometriosis. Conventional treatments have therefore been directed at the 
removal of all ectopic tissue. Medical therapies induce atrophy within the 
hormonally dependent ectopic endometrium so that they shrink in size and 
number, whilst surgical treatments achieve this by destroying or removing the 
implant. It is important to note that there is no correlation between laparoscopic 
findings with symptoms or fertility prognosis or recurrence rate and that the 
response to hormonal therapy has not been shown to always predict the 
presence or absence of endometriosis98,99. 
Current approaches for managing endometriosis are aimed mainly at treating 
symptoms of pain and infertility, while targeting disease progression and 
preventing recurrence. Treatment must be individualized, taking the clinical 
problem in its entirety into account, including the age, impact of the disease and 
the effect of its treatment on quality of life and plans for fertility. Long-term 
treatment of patients with chronic pelvic pain associated with endometriosis 
involves repeated courses of medical therapy, surgical therapy, or both. In such 
circumstances, a multi-disciplinary approach involving a pain clinic and 
counselling should be considered early in the treatment plan.  
4.2 Analgesics  
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as a first line 
treatment of endometriosis-associated pain even though very limited evidence 
supports their use. Studies showing elevated prostaglandin levels in peritoneal 
fluid and endometriotic tissue in women with endometriosis have supported 
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their use100. A Cochrane review on the role of NSAIDs in treating endometriosis 
related pain analysed one randomised controlled trial (RCT) comparing 
naproxen sodium (275mg, four times daily) with placebo but found no 
significance difference101,102. Another study that investigated the use of 
cyclooxygenase (COX)-2 inhibitor (rofecoxib) against a placebo (n=28) reported 
significant improvement of dysmenorrhea, dyspareunia and chronic pelvic pain 
in the treatment group103. Although, no side effects were reported in this study, 
rofecoxib has since been withdrawn by its manufacturer Merck because of its 
cardiovascular toxicity104. There were no RCTs found on the use of analgesics 
(paracetamol, aspirin, ibuprofen, opioids) for treating endometriosis-associated 
pain68.  
From a clinical perspective, the use of NSAIDs for the management of pain 
should be discussed with the side effects associated with frequent use of 
NSAIDs, including inhibition of ovulation, risk of gastric ulceration and 
cardiovascular disease105,106.  
4.3 Empirical Hormonal Treatment 
The European Society of Human Reproduction and Embryology (ESHRE) has 
suggested that empirical treatment should be started without a definitive 
diagnosis69. This is due to the invasiveness and cost of laparoscopic 
procedures, but also complimented by the ease of prescribing hormonal 
contraceptives, which suppress the menstrual cycle and improve pain 
symptoms, in addition to its contraceptive benefits. This may be more 
appropriate in young adolescents or in women that decide not to have a 
laparoscopy. If medical treatment relieves pain, many women may not be 
interested in whether or not their pain symptoms were due to peritoneal 
endometriosis107. Laparoscopy can then be performed if patients do not 
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respond favourably to the medical or hormonal treatments, so that 
endometriosis can be diagnosed and treated or excluded.  
4.4 Hormonal therapies for treatment of endometriosis related pains 
Endometriosis is a disease of women in their reproductive years associated with 
cyclical ovarian activity. Therefore, hormonal suppression is considered as a 
medical approach to treat the disease and its symptoms. Medical treatments 
theoretically have the ability to treat those implants not visible to the naked eye. 
Currently, combined oral contraceptives, progestogens, anti-progestogens, 
GnRH agonists and aromatase inhibitors are in clinical use. There are 
insufficient data to support the use of selective oestrogen receptor modulators 
and selective progesterone receptor modulators68. Hormonal treatments are 
also associated with varying side effects and there is a lack of evidence 
supporting the use of one hormonal treatment over another. Prescribing will 
therefore depend on the patient’s choice and treatment cost.  
4.4.1 Combined Oral Contraception (COCP) 
Modern low dose COCP is widely used as the first line treatment for patients 
with presumed endometriosis as it offers many practical advantages, including 
contraceptive protection and cycle control108. COCP has also been observed to 
reduce menstrual flow and decidualisation of endometriotic implants with 
decreased cell proliferation and increased apoptosis109.  
Although current guidelines suggest empirical treatment with analgesia, COCP 
or progestogens, there remains very limited evidence for the efficacy of COCP 
in treating endometriosis pain108. A Cochrane systematic review evaluating the 
efficacy of COCPs found one small RCT and concluded that COCP (0.02mg 
ethinyl estradiol with 0.15mg desogestrel daily, taken cyclically) was as effective 
as GnRH analogues for the relief of dyspareunia, dysmenorrhoea and non-
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menstrual pain108. Changing from cyclical to continuous treatment may improve 
symptoms, however, 14% of women on continuous COCP reported moderate to 
severe side effects110.  
4.4.2 Progestogens and Anti-progestogens 
Clinical observation of the apparent resolution of symptoms of endometriosis 
during pregnancy gave rise to treatment with medication containing a 
progestogen111. A recent Cochrane review concluded that 
medroxyprogesterone acetate (100 mg daily) was significantly more effective at 
reducing all symptoms when compared with placebo, however its use was 
associated with significantly more cases of acne and oedema112. There was no 
evidence of a benefit with depot or oral progestogens over other treatments 
(COCP or leuprolide acetate) for endometriosis related symptoms, however, 
progestogens are associated with a better side effects profile than COCP112.  
The levonogestrel-releasing intrauterine system (IUS) releases levonorgestrel 
(LNG) directly into the uterine cavity at a relatively constant rate of 
20 microgram per day for 5 years113. LNG exerts strong local progestational 
activity and renders the endometrium atrophic and inactive, although ovulation 
is usually not suppressed114.  RCTs on LNG-IUS showed that it significantly 
improved endometriosis related pain but this was not significantly different when 
compared with leuprolide acetate, a GnRH agonist115,116. However, LNG-IUS 
has a significantly better side-effects profile than GnRH. 
Danazol has also been shown to reduce endometriosis-associated pain, back 
pain and dyschezia when compared to placebo117. However, significant side 
effects including acne, non-reversible voice change, oedema, vaginal spotting, 
weight gain and muscle cramps, greatly reduced its usefulness68,118. 
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Anti-progestogen exerts anti-proliferative effects on the endometrium whilst 
maintaining serum oestradiol levels in the early to mid-follicular phase range 
thereby offering a better side effect profile by avoiding the bone mass loss and 
hypoestrogenism associated with progestogen only use112. However, in the 
recent Cochrane review, gestrinone was the only anti-progestogen evaluated in 
a RCT for endometriosis related symptoms and there was no evidence of 
significant benefit when compared to danazol or leuprorelin (a GnRH 
analogue)112.   
4.4.3 GnRH agonists  
GnRH agonists effectively deplete the pituitary of endogenous gonadotropins 
and inhibit further synthesis, thus inducing a hypoestrogenic state resulting in 
the interruption of the menstrual cycle, endometrial atrophy and amenorrhoea. 
A systematic Cochrane review of 41 RCTs concluded that GnRH agonist was 
more effective than placebo but inferior to the LNG-IUS or danazol in the relief 
of endometriosis-associated pain68,119. The review found a worse side-effects 
profile with the use of GnRH, which should be discussed with the patient when 
offering this treatment. The hypoestrogenic effects of GnRH agonist include loss 
of bone mass of up to 13% over a 6 months period (reversible with 
discontinuation of therapy), therefore the simultaneous use of hormonal add-
back therapy (oestrogens and/or progestagens or tibolone) is recommended120. 
The use of hormonal add-back therapy has not been shown to reduce the 
efficacy of GnRH121. This phenomenon may be explained by the oestrogen 
threshold theory, which suggests that a lower oestrogen levels is needed to 
protect the bone, cognitive function and avoid/minimise menopausal symptoms 
such as hot flushes, sleep disturbance, mood swings, than to activate 
endometriotic tissue122.  
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4.4.4 Aromatase inhibitors (AIs) 
AIs have been studied as treatment for endometriosis in spite of the 
controversies surrounding the evidence for increased expression of aromatase 
P450 in endometriotic tissue. The most common third-generation AIs, letrozole 
and anastrozole, are reversible inhibitors of the enzyme aromatase, competing 
with androgens for aromatase binding sites. The adverse effects are mostly 
hypoestrogenic and include vaginal dryness, hot flushes and diminished bone 
mineral density. Earlier reports of increased cardiovascular risks have not been 
substantiated.  
Existing evidence for the use of AIs for endometriosis pain are mostly moderate 
quality non-randomised studies or case reports with a lack of long-term effects 
evidence123,124. Due to their severe adverse effects, current (2014) ESHRE 
guidelines recommended that AIs should only be prescribed after all other 
options for medical or surgical treatment have been exhausted68. 
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Chapter 5 – Surgical Therapies 
5.1 Surgery for Endometriosis Associated Pain 
Surgical intervention may be initiated in the diagnosis or treatment of 
endometriosis after failed medical therapies125. A laparoscopic approach 
provides superior views of the pelvic organs and is associated with a less pain, 
shorter hospital stays, quicker recovery and better cosmesis. Laparotomy may 
be necessary for advanced disease with extensive adhesions or when there is 
involvement of adjoining organs. Surgical procedures include excision, 
fulguration or laser ablation of peritoneal endometriotic implants; excision, 
drainage or ablation of endometriomas; resection of rectovaginal nodules and 
adhesiolysis. Conservative surgery aims to treat all visible endometriotic lesions 
and restore normal pelvic anatomy.  
A Cochrane review of 5 RCTs concluded that there were significant benefits of 
operative laparoscopy for endometriosis at 6 and 12 months after surgery when 
compared to diagnostic laparoscopy alone or medical therapies125. Most of the 
patients included in the review did not have severe endometriosis. The excision 
of lesions would be preferred to obtain a histological specimen, although 
ablation and excision of peritoneal endometriosis were equally effective for 
treatment of chronic pelvic pain in women with mild endometriosis126,127. In 
severe endometriosis with DIE, ablative techniques are unlikely to be 
successful. 
An alternative strategy suggested for controlling endometriosis related pain was 
to interrupt the nerve pathways. A 2005 Cochrane review concluded that 
laparoscopic uterosacral nerve ablation offered no additional benefit over 
conservative surgery, while presacral neurectomy combined with laparoscopic 
ablation of endometriotic tissue significant improved dysmenorrhoea and 
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reduce severe midline pain at 6 months and 12 months128. However, performing 
presacral neurectomy requires a high degree of surgical skill, which was 
associated with increased risk of adverse effects such as bleeding, constipation, 
urinary urgency and painless first stage of labour. 
5.2 Surgery for Pain Associated with Endometriomas 
A Cochrane review concluded that laparoscopic excision of ovarian 
endometriotic cyst walls (3 cms) was superior to drainage and coagulation with 
bipolar diathermy in terms of recurrence of dysmenorrhoea, dyspareunia, non-
menstrual pain and risks of further surgery129. A more recent RCT comparing 
cystectomy and CO2 laser vaporization found the recurrence rate of 
endometriomas to be significantly higher at the 12 months postoperative period 
in the laser vaporization group, although there was no difference 60 months 
after surgery130. Whilst the superiority of excision over drainage and 
coagulation/ablation can be expected, concerns over excessive resection of 
ovarian tissue compromising future fertility remains. The risk of ovarian failure 
after bilateral ovarian cystectomies for endometriomas was reported at 2.4%131. 
5.3 Surgery for Deep Infiltrating Endometriosis (DIE) Associated Pain  
Deep infiltrating endometriotic nodules extend more than 5 mm beneath the 
peritoneum and may involve the uterosacral ligaments, pelvic side walls, 
rectovaginal septum, vagina, bowel, bladder or ureter. Bowel endometriosis 
usually affects the rectosigmoid colon and can be associated with symptoms 
such as bowel cramping, diarrhoea or dyschezia132. This has been estimated to 
occur in about 3.8–37% of the patients133. Treatment of colorectal 
endometriosis is difficult and challenging. Medical management of DIE with 
colorectal involvement is aimed at suppression of symptoms and often 
associated with significant side effects134. It is unclear whether medical 
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management in these cases prevents disease progression. Certainly, 
discontinuation of treatment commonly results in recurrence of symptoms135.  
It is widely agreed that severe endometriosis, especially in symptomatic DIE 
with colorectal involvement, will require surgical treatment136. Surgical strategies 
include superficial shaving, discoid resection or segmental resection of the 
involved bowel segments to remove the endometriotic nodules. Although there 
is an on-going debate about the indication for shaving nodules as opposed to 
segmental resection, most studies report an improvement in pain outcome, 
quality of life, gynaecological and digestive symptoms after surgery for 
colorectal endometriosis132,137. In patients who underwent bowel resection with 
anastomosis (n = 2036), Mueleman et al.132 reported complication rates of 2.7% 
(55/2036) for rectovaginal fistulae, 1.5% (30/2036) anastomotic leakages and 
0.34% (7/2036) abscesses. In patients who underwent either full thickness disc 
excision or superficial shaving (n = 1799), complications reported were 0.7% 
(12/1799) for rectovaginal fistulae, 0.7% (12/1799) anastomotic leakages and 
0.3% (6/1799) pelvic abscesses. Although direct comparison of the different 
surgical techniques was not possible, there was a lower recurrence rate in 
women who underwent bowel resection anastomosis (5.8%) versus disc or 
superficial excision (17.6%).  
Surgical treatment of bladder endometriosis usually involves excision of the 
bladder lesion and primary closure of the bladder wall. Ureteral lesions may be 
excised after stenting the ureter; however, in the presence of intrinsic lesions or 
significant obstruction, segmental excision with end-to-end anastomosis or re-
implantation may be necessary.  
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5.4 Hysterectomy for Endometriosis 
Hysterectomy with bilateral salpingo-oophorectomy is generally reserved for 
women with debilitating symptoms attributed to endometriosis who have 
completed childbearing and in whom medical therapies have failed. There were 
no RCTs found on hysterectomy (with or without oophorectomy) for treating 
endometriosis-associated pain, but a non-systematic review concluded that 
hysterectomy for chronic pelvic pain was successful in many, but not all 
women68,138. The success of this surgical approach was attributed to debulking 
of the disease and the resulting surgical menopause causing atrophy of 
endometrial tissue. Case series have shown that hysterectomy with ovarian 
conservation presents a 6-fold greater risk for the development of recurrent pain 
and an 8.1-times greater risk of reoperation139.    
A Cochrane review found two RCTs investigating recurrence of pain and 
disease in women with endometriosis who use hormone therapy following 
bilateral-oophorectomy120. In the first RCT, transdermal oestrogen (0.05 
mg/day) with cyclical oral medroxyprogesterone acetate (10 mg per day) for 12 
days each month was compared with continuous tibolone (2.5 mg/day) in 
women who had uterine conservation surgery. After 12 months, four (40.0%) 
women in the first group and one (9.1%) in the second experienced moderate 
pelvic pain. In the second RCT, continuous transdermal oestrogen with cyclical 
oral progesterone was compared with no treatment. After 45 months, four 
(3.5%) patients in the treated arm and none in the non-treated arm reported 
recurrence of pain. Although there was no statistically significant difference, the 
authors highlighted residual disease as a risk factor to recurrence.  
Considering the physiology of endometrial tissue, it seems sensible that 
postoperative hormone replacement should include both oestrogen and a 
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progestogen. The 2014 ESHRE guidelines suggest the use of oestrogen and 
progestogen therapy or tibolone for the treatment of menopausal symptoms in 
women with surgically induced menopause because of endometriosis, at least 
up to the age of natural menopause68.   
5.5 Infertility 
Women with endometriosis are confronted with endometriosis associated pain, 
infertility or both. In women with minimal to mild endometriosis, suppression of 
ovarian function with medical treatments including danazol, GnRH analogues or 
COCP, to improve fertility is not effective and should not be offered for this 
indication alone140. In the same groups of women, operative laparoscopy with 
adhesiolysis is effective in increasing the pregnancy rate when compared to 
diagnostic laparoscopy alone125.   
In moderate to severe endometriosis, the overall data suggest that laparoscopic 
surgery is effective for the treatment of infertility141,142. The spontaneous 
pregnancy rate following expectant management was 30% in moderate disease 
and 0% in severe disease143. After operative laparoscopic treatment, including 
the excision of endometriotic lesions and adhesiolysis, spontaneous pregnancy 
rate improved to 57–69% in cases of moderate endometriosis and 52–68% in 
severe disease. Combination of medical and surgical treatment either 
preoperatively or postoperatively has not been found to improve fertility and 
may delay fertility treatments144. 
In the presence of ovarian endometriomas, excision of the cyst capsule 
increased the postoperative spontaneous pregnancy rate, when compared to 
drainage and electrocoagulation of the cyst wall129. However, as discussed 
previously both techniques can potentially diminish ovarian reserve.   
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Chapter 6 - Adhesions 
6.1 Introduction 
Adhesions are connective tissue bridges or internal ‘scars’ that form after 
trauma involving the peritoneum. The most common cause of adhesions is 
previous surgery. Other aetiology includes infection, chemical irritation, trauma, 
endometriosis and foreign body reactions including sutures. For the majority of 
women, adhesions do not appear to have any particular consequences, but in 
some the morbidity in terms of abdominal or pelvic pain, intestinal obstruction 
and female infertility are severe.  
Even when surgery is performed with strict adherence to microsurgical 
principles, prevalence of pelvic adhesions following laparoscopic surgery for 
severe pelvic endometriosis varies between 50 and 100%145,146. The 
consequences of adhesion formation include subfertility, development of 
chronic abdominal pain, dyspareunia and intestinal obstruction147. Subsequent 
surgical procedures become more difficult. The Surgical and Clinical Adhesions 
Research study found that 5% readmissions 10 years after open gynaecological 
surgery were due to adhesions148,149. It is estimated that in the first year after 
lower abdominal surgery, the cost of adhesion related readmissions in the UK is 
£24.2million, which increases to £95.2 million over the subsequent nine 
years150. It is estimated that the National Health Service (NHS) could save 
£700,000 per year if an anti-adhesion agent that reduced adhesions by 25% 
and cost £110 was used or, at worst, that this approach would be cost-
neutral151. This significant socioeconomic cost of adhesions has prompted a 
search for strategies, which may lead to a safe reduction or prevention of 
adhesions. Strategies have focussed on minimising surgical trauma, the use of 
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barriers to prevent adhesions and the use of medication both locally and 
systemically.  
6.2 Pathophysiology 
Adhesion formation may be considered the result of a normal physiological 
response to a peritoneal injury that has gone unchecked. Injury to intact 
peritoneal surfaces creates two raw edges and initiates a complex cascade of 
events which involves an increase to vessel permeability, release of 
inflammatory cells, increase in leukotrienes and prostaglandins and decrease in 
plasminogen activity152. The peritoneal defect is initially sealed by a 
proteinaceous exudate consisting of fibrin deposits, leukocytes and 
macrophages. Fibrin is a sticky substance and the exudate establishes a bridge 
between the damaged surfaces153. The function of fibrin in the body is to restore 
injured tissues. This process usually starts within 3 hours of peritoneal injury154. 
Peritoneum would normally contain high levels of plasmin and other fibrinolytic 
agents, which could completely degrade fibrin during normal healing155. 
However, any abnormity of this process results in an imbalance in the healing 
pathway, leading to a decrease in the amount of plasminogen and resulting in 
the organisation of fibrin152. The presence of organised fibrin is thought to 
initiate the activation of an adhesion cascade and within five days, the fibrin 
mesh is invaded by proliferating fibroblasts, which replace the fibrin with more 
durable components of the extra-cellular matrix such as collagen153,156.  
General agreement exists between investigators on the time for regeneration of 
peritoneum157. Ellis et al.158 and Hubbard et al.,159 reported that healing occurs 
in 5-6 days in the case of parietal peritoneum. Peritoneal defects 2x2cm and 
0.5x0.5cm were both completely covered by a continuous sheet of mesothelium 
3 days after peritoneal injury158. 
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In terms of adhesion prevention, the minimum postoperative interval required 
for adhesion prevention was established to be 36 hours157,160.  Harris et al.,160 
studied the kinetics of peritoneal adhesion prevention and found that the 
susceptibility to adhesion formation could be eliminated in the first 36 hours 
after peritoneal injury. In their evaluation of different antiadhesive agents, the 
magnitude of adhesion prevention was direction proportional to the agent’s 
ability to remain at the site of injury during this critical period of adhesion 
formation.  
6.3 Adhesion Prevention  
Adhesiolysis is the only available treatment for adhesions, however, controversy 
regarding its efficacy continues161. The focus of adhesion management is 
prevention and it is hoped that by eliminating the incidence of adhesions, there 
should be a benefit noted in pain reduction and improved fertility rates.  
Microsurgical technique principles include minimizing serosal trauma, use of 
atraumatic instruments, inert suture materials, careful tissue handling, 
prevention of tissue desiccation and ensuring meticulous haemostasis are 
thought to reduce but not completely prevent the occurrence of adhesions162. 
Laparoscopic surgery embraces the principles of microsurgery, with careful 
tissue handling, magnification provided by the laparoscope when held close to 
the tissue and strict attention to haemostasis to coagulate individual bleeding 
vessels.  
Other adhesion prevention modalities target key steps in the fibrin formation 
cascade or attempts to physically separate raw peritoneal surfaces. These can 
be divided into fluid, gels, pharmacological and barrier163.  
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6.3.1 Fluids 
For many years, laparoscopic surgeons have used Ringer’s lactate 
(Hartmann’s) as an irrigation fluid and many add 5IU of heparin per litre, which 
appears to help limit the formation of large blood clots that can be difficult to 
remove laparoscopically. Reich164 introduced a concept of hydroflotation at the 
end of his laparoscopic procedures, often leaving one to two litres of sodium 
lactate, in an attempt to prevent subsequent adhesion formation. Ultrasound 
studies shows that this fluid is completely absorbed within 72hours.  
A glucose polymer solution, 4% icodextrin (Adept, Baxter, Berkshire, UK) has 
been used extensively for patients on peritoneal dialysis with little evidence of 
adhesion formation despite repeated passage of catheters for renal dialysis. 
Icodextrin is an -1-4-linked glucose iso-osmolar and non-viscous polymer 
produced by the hydrolysis of corn starch. It is a substrate for amylase, which is 
widely distributed throughout the body but is not present in the human 
peritoneal cavity, therefore, when icodextrin is instilled intraperitoneally, it is 
largely retained within the peritoneal cavity. Absorption of the polymer occurs 
gradually via the lymphatic system into the systemic circulation. Studies have 
shown that icodextrin placed into the peritoneal cavity at the end of surgery will 
stay in situ for up to 3 to 5 days165,166. 
Hyskon (Pharmacia, Uppsala, Sweden) which consist of 32% dextran 70 
(200mls) has been widely used as an intraperitoneal instillant. It works on the 
principle of drawing fluid into the peritoneal cavity by its osmotic property to 
produce hydroflotation. Dextran’s use has been limited due to a number of 
complications including pleural effusion, pulmonary oedema, elevated liver 
enzymes, ascites, labial oedema and rarely, anaphylactic shock167. Most 
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centres have discontinued the use of Hyskon and it is no longer commercially 
available in the UK. 
6.3.2 Gels 
Gels are thought to decrease adhesion formation by separating denuded 
tissues. Derivatives of hyaluronic acid form the basis of a number of 
antiadhesion gels. Hyaluronic acid is a major component of many body tissues 
and fluids, where it provides physically supportive and mechanically protective 
roles168. Hyaluronic acid is a linear polysaccharide with repeating disaccharide 
units composed of sodium D-glucuronate and N-acetyl-D-glucosamine. 
SepraSpray (Genzyme Corporation, Cambridge, MA, USA) contains hyaluronic 
acid and carboxymethylcellulose (CMC) powder. It is applied to relevant tissues 
via a preloaded delivery device. SepraCoat (Genzyme Corporation) is a dilute 
hyaluronic acid solution that is applied before and after surgery. Hyalobarrier 
gel (Nordic Pharma, Reading, UK) contains auto-cross-linked hyaluronic acid. 
Intergel (Gynaecare, Lifecore Biomedical, Chaska, MN, USA) which contains 
ferrous hyaluronic acid, has been withdrawn from the market because of reports 
of increased postoperative pain and sclerosing peritonitis.  
Polyethylene glycol (PEG) based gels are also available. CoSeal (Baxter) is 
formed by mixing a powder and a liquid intraoperatively, both of which contains 
PEG. SprayGel (Confluent Surgical Inc., Waltham, MA, USA) is formed by two 
PEG containing liquid precursors, which create a cross-linked gel when 
combined. Intercoat (FzioMed, San Luis Obispo, CA, USA) is an Oxiplex/AP 
viscoelastic gel composed of polyethylene oxide (PEO), which is very similar to 
PEG but has a different molecular weight, and CMC.  
A recent Cochrane review concluded that hydroflotation agents and gels appear 
to be effective adhesion prevention agents for use during gynaecological, 
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compared to no treatment163. Participants who received a hydroflotation agent 
(OR 0.34, 95% CI 0.22-0.55, P < 0.00001) or a gel (OR 0.25, 95%CI 0.11-0.56, 
P = 0.0006) were significantly less likely to have adhesions at second look 
laparoscopy (SLL) when compared with those who received no treatment. 
However, there was a large gap in evidence when clinical outcomes such as 
pain improvements or live birth rates were considered. One RCT did assess 
pelvic pain but found no evidence of pain improvement when 4% icodextrin was 
compared with saline169.  
6.3.3 Pharmacological Agents 
Steroids have been used to prevent adhesions and can be administered 
intraperitoneally during surgery or via hydrotubation postoperatively. Steroids 
and antihistamines (e.g. promethazine) act as immunomodulating agents and 
were used in the belief that they may promote fibrinolysis during healing, 
without hindering the healing process.  
As discussed, heparin has often been used as an intraoperative irrigant. Other 
pharmacological agents used to prevent adhesions include noxytioline (an 
antibacterial agent), promethazine (antihistamine) and reteplase (thrombolytic 
drug) have also been instilled intraperitoneally. A nasal GnRH agonist has also 
been used preoperatively and postoperatively and may work by decreasing 
oestrogen-related growth factors and promoting fibroblasts.  
There was no evidence for adhesions reduction, pain improvements or live birth 
rates with any pharmacological agent163.  
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6.3.4 Barrier Agents 
In theory, an inert physical materials placed between traumatised peritoneal 
surfaces can prevent mechanical contact and allow independent mesothelial 
healing of each traumatised peritoneal surface. Several synthetic barriers with 
different characteristics are commercially available, oxidised regenerated 
cellulose (ORC), expanded polytetrafluorethylene (PTFE) and modified 
hyaluronic acid with CMC.  
ORC is commercially available as Interceed (Johnson & Johnson, Cincinnati, 
USA) and can be cut as necessary. It does not require suturing, is absorbable 
and may be applied laparoscopically. It is applied over raw tissue surfaces at 
the end of surgery after all irrigation fluid has been removed and haemostasis 
achieved. The most important step to maximise the efficacy of Interceed is via 
haemostasis, as the presence of bleeding renders it ineffective170. It forms a 
gelatinous protective coat within eight hours of application, and is broken down 
into its monosaccharide constituents and absorbed within two weeks. The fabric 
nature of Interceed can make passage through a laparoscopic port 
cumbersome. 
Expanded PTFE (Gore-Tex) is marketed as Preclude (W. L. Gore & Associates, 
Arizona, USA). It is inert but must be sutured in place and is permanent. 
Preclude is approved for use for peritoneal repair but not for adhesion 
reduction. When placed over traumatised tissue, it has been shown to reduce 
adhesion formation and reformation, regardless of whether haemostasis has 
been achieved171. Preclude has the advantage of being unaffected by the 
presence of blood, however, it is permanent and unless surgically removed can 
become engulfed by an adhesion like membrane.   
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Seprafilm (Genzyme Corporation, Cambridge, USA) an adhesion barrier 
composed of chemically derived sodium hyaluronate and CMC. It is a nontoxic, 
non-immunogenic, biocompatible and biodegradable material that has been 
modified to prolong its intraperitoneal residence time. It is absorbed from the 
peritoneal cavity within seven days and is completely excreted from the body 
within 28 days172. Unfortunately, the sheets are also rather firm, non-compliant 
and difficult to place at the required site during laparoscopic surgery153. 
A Cochrane review of barriers agents concluded that Interceed and Preclude 
appeared to reduce the incidence of postoperative adhesions162. Interceed was 
associated with reduced incidence of both new formation and reformation of 
pelvic adhesions following laparoscopic surgery or laparotomy (OR 0.39, 95% 
CI 0.28-0.55). However, there were insufficient data to support its use to 
improve pregnancy rates. Preclude was more effective than no treatment (OR 
0.21, 95% CI 0.05-0.87) or Interceed (OR 0.16, 95% CI 0.03-0.80) in adhesion 
prevention but its usefulness is limited by the need for suturing and removal at a 
later date. There was no evidence that Seprafilm was effective in preventing 
adhesion formation.  
6.4 Conclusion  
Although gels and 4% icodextrin has shown efficacy in reducing adhesions, 
there is limited evidence on their effects on clinical outcomes. Ultimately, the 
search for best anti-adhesion agent or strategy continues and further research 
is required evaluate existing and newer modalities.  
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Chapter 7 - Ultrasound 
7.1 Introduction 
The use of ultrasound has revolutionised the practise of gynaecology in the past 
three decades. The first published clinical use of ultrasound was in the field of 
gynaecology when Professor Ian Donald used transabdominal ultrasound to 
differentiate between solid and cystic abdominal masses173. The first clinically 
useful ultrasound machine was made possible by a combination of Professor 
Donald’s knowledge of SONAR, acquired during the 2nd World War and the 
technical expertise of an engineer, Tom Brown, who had an interest in the use 
of ultrasound in metallurgy, to create the first clinically useful ultrasound 
machine. Its ability to provide instant, clinical information using a safe, non-
invasive modality was transformational and has revolutionised clinical practice. 
TVS is now the default investigational tool for any women presenting with a 
gynaecological complaint.  
7.2 Principles 
Medical ultrasound is based on the principle of passing a current through a 
piezoelectric crystal to create ultrasound wave pulses. When an electric field is 
placed across a slice of one of these materials, the material contracts or 
expands. If the electric field is reversed, the effect on the material is also 
reversed. If the electric field keeps reversing, the crystal alternately contracts 
and expands. So a rapidly alternating electric field causes the crystal to vibrate. 
The vibration is largest when the electric field stimulates a natural frequency of 
the crystal (resonance). The vibrations are then passed through any adjacent 
materials, or into the air as a longitudinal wave i.e. a sound wave is produced. 
When these sound waves are applied to the tissue within the body, they 
encounter an interface between tissues of differing density or acoustic 
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impedance. As a result, a proportion of the emitted sound waves will be 
reflected back towards the piezoelectric element. This reflection is called an 
echo. The piezoelectric effect also works in reverse. If the crystal is squeezed or 
stretched, an electric field is produced across it. So if ultrasound hits the crystal 
from outside, it will cause the crystal to vibrate in and out, and this will produce 
an alternating electric field. The resulting electrical signal can be amplified, 
processed and converted into an image or visual representation of the varying 
densities within the body tissue. 
7.3 Image formation 
7.3.1 Brightness mode image formation 
A brightness-mode or B-mode image is a cross-sectional image representing 
tissues and organ-boundaries within the body. The image is constructed from 
echoes generated by the reflection of ultrasound waves at tissue boundaries. 
Each echo is displayed at a point in the image, which corresponds to the 
position of its origin in the tissue being isolated. The brightness of the image at 
each point is related to the strength or amplitude of the echo, giving rise to the 
term brightness mode or B-mode174. 
7.3.2 Transvaginal ultrasound (TVS) 
The frequency of ultrasound pulses used is a compromise between image 
resolution and the depth of penetration required. Higher ultrasound frequency 
results in better image resolution but there is greater attenuation of the beam 
within the tissues. Therefore, transabdominal ultrasound probes, which have to 
pass through multiple tissue layers before reaching the abdominal cavity, tend 
to use lower frequencies (3.5-5MHz) at the expense of image resolution. The 
ability of TVS probes to get much closer to the organs of interest enables the 
use of higher frequencies (8-15MHz), leading to much higher image resolution.  
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7.4 Doppler 
7.4.1 The Doppler effect  
When ultrasound is reflected from a moving surface, the frequency of the sound 
is altered slightly in a manner that depends on the speed of movement of the 
surface. This is due to the Doppler effect. When the object emitting the waves is 
stationary the observed frequency is the same as the emitted frequency, 
however if the sound source is moving towards the observer, the experienced 
frequency is higher as the sound waves become more compressed and the 
opposite happens if the sound source is moving away from the observer. This 
change in frequency is called the Doppler shift and is proportional to the relative 
velocity of the source to the observer. Evaluation of these Doppler shifts, 
alongside knowledge of the transmitted ultrasound frequency, the velocity of 
sound through the tissue and the angle of insonation, allow the calculation of 
the velocity of blood passing through the vessel175. This effect can be applied 
clinically and is used to assess the velocity of blood flow through blood vessels. 
This estimated velocity of blood flow over time can be shown on the ultrasound 
machine as a tracing (Figure 6). 
7.4.2 Colour Doppler imaging 
Colour Doppler imaging is a technique that combines anatomical information 
derived using ultrasonic pulse-echo techniques with velocity information derived 
using ultrasonic Doppler techniques to generate colour-coded maps of tissue 
velocity superimposed on grey-scale images of tissue anatomy. The velocity 
signals are presented as a colour coded overlay, superimposed on the real-time 
B-mode image. This allows production of an angiogram-like map that provides 
information on the morphological arrangement of the vascular tree in the tissue 
  58 
of interest. While its sensitivity is good enough to enable visualisation of vessels 
smaller than one millimetre, it is restricted by its reliance on frequency shifts176. 
7.5 Ultrasound and Adhesions 
Improvement in the quality of ultrasound equipment and examination technique 
has made TVS an accurate and reliable test for detecting pelvic adhesions and 
assessing the severity of endometriosis. Our group demonstrated that targeted 
TVS was an accurate test to establish the severity of pelvic endometriosis, and 
was particularly accurate in detecting severe endometriosis, sensitivity 0.85, 
specificity 0.98 and LR+ was 43.5, and LR− was 0.1589. A subsequent 
reproducibility study found high level of agreements for the detection of 
individual features of endometriosis including ovarian adhesions (kappa, 0.751 
to 0.837) and pouch of Douglas obliteration (kappa 0.963 to 0.982)177. In the 
diagnosis of ovarian adhesions, TVS was found to be particularly effective in 
the hands of one of the ultrasound observers who achieved a sensitivity 0.82, 
specificity 1.00, positive predictive value (PPV) of 1.00 and NPV of 0.84.  
Okaro et al.178 examined women with chronic pelvic pain prior to diagnostic or 
operative laparoscopy for the presence of ovarian adhesions and classified 
them as either mobile or fixed. They found a high level of agreement (kappa, 
0.80) between ovarian mobility on TVS and laparoscopy. Prior to this, Guerriero 
et al.179 used the presence of one of three features to suggestive the likelihood 
of ovarian adhesions: blurring of the ovarian margins, inability to mobilise the 
ovary with abdominal palpation (fixation) and an increased distance of the ovary 
from the transvaginal probe. They found that the presence of a fixed ovary gave 
a moderate level of agreement (kappa, 0.51) and this was more accurate than 
blurring of the ovarian margins and detection of increased ovarian distance from 
the transvaginal probe.  
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In a more recent study, Guerriero et al.180 used a combination of applying 
pressure between the uterus and ovary with the transvaginal probe and gentle 
abdominal palpation to assess for ovarian mobility. This technique gave a 
sensitivity of 89%, specificity of 90%, LR+ was 8.92, LR- 0.12 and a high kappa 
agreement of 0.74. 
Two studies have reported lower than expected accuracies with ultrasound in 
the diagnosis of ovarian adhesions. Ubaldi et al.181 found that poor definition of 
pelvic structures at TVS had a relatively low sensitivity of 61% in the detection 
of pelvic adhesions, and Yazbek et al.182 suspected pelvic adhesions in 143 
women with adnexal masses when the pelvic tumour could not be mobilized by 
using gentle pressure with the transvaginal probe. The sensitivity obtained was 
only 44% with a specificity of 98%. 
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Figure 3 B-mode ultrasound of an ovarian endometrioma with a vascular corpus luteum illustrated by colour Doppler 
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Figure 4 B-mode ultrasound of a rectovaginal endometriotic nodule 
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Figure 5 B-mode ultrasound of a bladder endometriotic nodule 
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Figure 6 B-mode ultrasound image with Doppler velocimetry of a blood vessel within a malignant ovary 
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Chapter 8 
8.1 Rationale for study  
Prevalence of pelvic adhesions following laparoscopic surgery for severe pelvic 
endometriosis varies between 50 and 100%183. Postoperative adhesions most 
commonly affect the ovaries and the pouch of Douglas184. This can result in 
chronic pelvic pain, dyspareunia, intestinal obstruction and infertility145. A wide 
range of interventions have been tried to reduce postoperative pelvic 
adhesions, but none has gained wide acceptance or been shown to be clinically 
effective. Intra-operative suspension of the ovaries to the anterior abdominal 
wall has been used to facilitate ovarian retraction especially during surgery for 
severe pelvic endometriosis185. Two small observational studies have suggested 
that temporary ovarian suspension for four to seven days following surgery for 
severe endometriosis may reduce the frequency of postoperative pelvic 
adhesions186,187. A prospective RCT will be needed to assess effect of 
postoperative temporary ovarian suspension on the prevalence of postoperative 
ovarian adhesions.  
8.2 Study design 
There is a hierarchy of strength of evidence concerning efficacy of treatment. 
Case reports are weakest and RCTs are strongest, with various observational 
and retrospective designs in between. Sound scientific clinical investigations 
almost always demand that a control group be compared against a new 
intervention. Controls may be on placebo, no treatment, usual or standard care 
or a specified treatment. Randomisation is the preferred way of assigning 
participants to control and interventions groups.  
A clinical trial is a prospective study comparing the effect and value of 
interventions against a control. Most trials have a parallel design, where the 
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intervention and control group are followed simultaneously from the time of 
allocation to an end point. A modification of the parallel design is the cross-over 
trial, which uses each participant at least twice, once as a member of the control 
group and at least once as a member of the intervention group.  
8.3 Randomised control trials (RCTs) 
RCTs are the most rigorous way of determining whether a cause-effect relation 
exists between treatment and outcome. The assignment of the subject to a 
group is determined by the formal procedure of randomisation. Participants in 
both groups are treated identically except for the experimental treatment. 
Ideally, participants and clinicians should remain unaware of which treatment 
was given until the study is completed, although such double blind studies are 
not always feasible. Analysis is focused on estimating the size of the difference 
in predefined outcomes between intervention groups. Participants are normally 
analysed within the group to which they were allocated, irrespective of whether 
they experienced the intended intervention (intention to treat analysis) 
There are three advantages of the randomised design over other methods of 
selecting controls188. Firstly`, randomisation removes the potential of bias in the 
allocation of participants to the intervention group or the control group. An 
allocation bias could occur either because the investigator or participant 
influences the choice of intervention. This influence may be conscious or 
subconscious. The direction of the allocation bias may go either way and can 
easily invalidate the comparison. The second advantage is that randomisation 
tends to produce comparable groups. Prognostic factors and other 
characteristics of the participants will usually be evenly balanced between the 
intervention and control groups. Although this does not mean that all baseline 
variables will be perfectly balanced between the two groups, it does mean that 
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for independent covariables, the overall magnitude and direction of the 
differences will tend to be equally divided between the two groups. Often many 
covariates are strongly associated, therefore any imbalance in one would tend 
to produce imbalances in others. The third advantage is that the validity of 
statistical tests of significance is guaranteed. The process of randomisation 
makes it possible to ascribe a probability distribution to the difference in 
outcome between treatment groups receiving equally effective treatments and 
thus to assign significance levels to observed differences. If randomisation is 
not used, further assumptions concerning the comparability of the groups and 
the appropriateness of the statistical models must be made before the 
comparison will be valid.  
Not all clinical studies can use randomised controls. If the prevalence of the 
disease is so rare that a large enough population cannot be obtained, only 
case-control studies might be possible.  
Double blinding ensures that the preconceived views of subjects and clinicians 
do not bias the assessment of outcomes. While ‘intention to treat analysis’, 
maintains the advantages of random allocation, which may be lost if subjects 
were excluded from analysis in cases of withdrawal or failure to comply.  
Although RCTs are powerful tools, their use is limited by ethical, emotional and 
practical concerns189. Exposing patients to an intervention believed to be 
inferior to current treatment is often considered unethical. Many clinicians would 
feel that they must not deprive a participant from receiving a new therapy or 
intervention, which they believe to be beneficial, regardless of the validity of the 
evidence for that claim. On the other hand, failure to perform trials may result in 
harmful treatments being used.  
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In some circumstances, a RCT may not be feasible because of difficulties with 
randomisation or recruitment. Indeed, once an intervention becomes 
widespread, it can prove impossible to recruit clinicians willing to “experiment” 
with alternatives. Strong patient preferences may also limit recruitment and bias 
outcomes if not accommodated within the study design. Another limiting factor 
is that RCTs are generally more costly and time consuming than other studies.  
8.4 Cross-over study design 
A cross-over study design is a special case of RCT. The essential feature 
distinguishing a cross-over trial from a conventional parallel-group trial is that 
each participant serves as his/her own control. The crossover design thus 
avoids problems of comparability of study and control groups with regard to 
confounding variables such as age and sex. Thus, the measured effect of the 
intervention is the difference in an individual participant’s response to 
intervention and control.  
Moreover, the crossover design is advantageous regarding the power of the 
statistical test carried out to confirm the existence of a treatment effect. 
Crossover trials require smaller sample sizes than parallel-group trials to meet 
the same criteria in terms of type I and type II error risks.  
8.5 Trial planning and design 
The first trial meeting was held on November 2008. After establishing the aim of 
trial, the group were alerted to a previous attempt to perform this study in 2003. 
Unfortunately, the earlier study did not progress beyond protocol development.  
All study materials from original study were obtained from the chief investigator 
who was part of the new trial team. The joint Research and Development (R&D) 
Office was also contacted to obtain trial details from the original trial. 
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8.6 The original study  
In 2003, a trial was planned to perform temporary ovarian suspension for 3 days 
post laparoscopic surgery with a repeat diagnostic laparoscopy scheduled 3 
months after the primary surgery to assess for pelvic adhesions. A prospective, 
cross-over design, double blind RCT, where women would act as their own 
control was intended. It was calculated that 20 women would be needed based 
on an estimate of the prevalence of adhesion following surgery. The original 
study received ethics approval and was registered in the R&D department (ID: 
003/0279). 
8.7 Risk assessment 
It was essential for us to examine the trial design, population and procedures to 
identify specific areas of vulnerability associated with the trial conduct and why 
the original trial was unsuccessful. This was to allow for risk avoidance 
strategies, safety monitoring procedures and trial management plans to be 
included in the study protocol.  
Risk assessment were undertaken in parallel with protocol development and 
reassessed periodically over the lifetime of a trial to account for new information 
and issues that became apparent after the commencement of the trial. Risk 
assessments are considered in two parts: 
1. Risks of intervention to participant’s safety  
2. Risks associated with the protocol and study procedures including the 
clinical procedures, participant rights related to consent, protection of data 
and reliability of trial results. 
Every effort was made to identify potential hazards and consider the 
appropriate risk avoidance or optimal monitoring strategy. The ability of the trial 
participants to give fully informed consent needed to be considered. It was 
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essential that personal data collected during the course of the study were 
stored securely and accessed only by authorised staff.  
The aim was to create a robust study design with simple and relevant eligibility 
criteria, clear and objective outcome measures, a properly generated 
randomisation schedule and randomisation method that prevents the prediction 
of treatment allocation, a simple intervention that is easy to apply, sufficient 
power to detect realistic effects of the intervention and attempts to minimise risk 
of missing key data. 
In our trial planning, our first concern was with regards to the duration of our 
intervention. The majority of patients after extensive laparoscopic surgery would 
require hospital stay of between one to two days after surgery. An ovarian 
suspension period of three days that was proposed in the original study would 
have required trial participants to either extend their stay in hospital or be 
discharged with suspension sutures in situ. Our review of the evidence 
suggested that although adhesions takes up to seven days to form, 
susceptibility to adhesion formation may be decreased or eliminated in the first 
36 hours after peritoneal injury (Chapter 6.2). After reviewing the evidence on 
adhesion prevention, we decided to reduce the minimal suspension period to 36 
hours.  
The original study also received ethical approval for a second diagnostic 
laparoscopy to assess the outcome of ovarian suspension as an intervention. 
This repeat surgery may have reduced the uptake of the original trial. To 
improve our patient acceptability and safety, we decided to use TVS to assess 
our intervention outcome. TVS would give us a comparable result whilst 
crucially avoiding the need for repeat surgery.  
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8.8 Statistical Preparation 
A statistician (Pauline Rogers) was recruited from the University College 
London Biomedical Research Centre at the planning stages of our trial and the 
first statistical meeting was conducted in February 2009.  
Pauline provided us with advice on the development of our study protocol, 
deciding on appropriate statistical outcomes and later helped generate a 
randomisation schedule. 
However, in our reassessment of the original study protocol, it became apparent 
that the original sample size calculations performed in the for the 2003 study 
had to be re-examined.  
8.9 Sample Size Preparation 
Our RCT plan involved women who received routine laparoscopic treatment for 
severe pelvic endometriosis to have one ovary randomised to temporary 
ovarian suspension and the other ovary unsuspended postoperatively. The 
primary outcome is the binary variable of the prevalence of ovarian adhesion 
three months after surgery with assessed using TVS.  
In order to perform a sample size calculation, the prevalence of ovarian 
adhesions on TVS, three months after routine laparoscopic treatment of severe 
pelvic endometriosis, without ovarian suspension had to be determined. As this 
information was not available, a pilot study was proposed.  
8.10 Sample Size Calculation 
A pilot study was completed between March 2009 and June 2009 (Chapter 10). 
The prevalence of ovarian adhesions per ovary, without ovarian suspension, 
was 18/32 (56.3%). For the sample size calculation, this was approximated to 
60%. A clinically significant improvement was defined as a 50% reduction in the 
prevalence of postoperative ovarian adhesions. The sample size calculation 
  71 
assumed that at three months’ postoperative review, 60% of the non-
suspended ovaries will exhibit ovarian adhesions and 30% of the suspended 
ovaries will exhibit ovarian adhesions.  
The software provided by Machin et al.190 was used to calculate the sample size 
for paired binary data. The calculation assumed that the response to 
suspension is independent to the response to non-suspension. The intra-class 
correlation coefficient for the presence of adhesions three months after surgery 
was 0.52. Assuming two-sided 5% significance, 80% power and a 54% 
proportion of discordant pairs, 45 women were required for the study. Allowing 
for a possible 10% dropout during the follow up period, we had planned to 
recruit at least 50 patients for the study. 
8.11 Randomisation 
Opinions regarding the efficacy of a newly proposed intervention will vary 
among investigators. Randomisation may be a problem for physicians who 
believe that they must be able to convey to their patients a treatment course of 
action. A researcher however must accept an uncertainly, because it would be 
unreasonable to expect that an individual investigator has no preference. The 
concept of ‘clinical equipoise’ was proposed, which is the presence of 
uncertainty to the benefits or harm from an intervention in the medical 
community that is a justification for a clinical trial191. Until an intervention has 
been proven beneficial, randomisation is the most ethical approach and 
quickest way to reach this conclusion192. 
Our study participants were randomised into two groups, one group had left 
ovarian suspension and the other group had right ovarian suspension. Block 
randomisation was used with three varying block sizes of minimum size four. 
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The randomisation schedule was produced by our statistician (Pauline Rogers) 
using the Stata command ralloc (StataCorp, College Station, TX, USA). 
When a participant was recruited to the trial, the anaesthetist who was not a 
member of the research team, opened consecutive randomisation envelopes 
and informed the principal surgeon of which ovary to suspend. 
Only the patient’s randomisation number was recorded in the patient’s 
operation notes. A label was attached to the operation notes to define (i) the 
randomisation number, (ii) the operation date and time and (iii) the time to 
remove the sutures. The principal surgeon was under strict instructions not to 
discuss the suspension details with other members of the study team or clinical 
team responsible for the postoperative care or with the patient about which 
ovary had been suspended.  There was no documentation of the randomisation 
site in the patient’s notes. 
At the end of the study, the randomisation was unblinded for analysis and 
details of the ovarian suspension were added to each participant’s record. 
Pauline Rogers kept a copy of the randomisation schedule on her computer in 
her personal area.  A second copy of the randomisation schedule was kept with 
the sister in charge of the ward in a sealed envelope. This was in case of the 
need for emergency unblinding. Unblinding would have only taken place on 
instruction from the chief investigator or principal investigator. 
8.12 Protocol development 
A study protocol is often viewed as a written agreement between the 
investigators, participants and scientific community. It describes the objectives, 
design, methodology, statistical considerations and organisation of a clinical 
trial. It also provides information on the background and rationale for a trial and 
outlines the study plan of the trial. The protocol also serves as a document to 
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assist communication among those working in the trial and should be made 
available to others upon request.  
A protocol should be developed before the onset of participant recruitments and 
should remain essentially unchanged except perhaps for minor updates. 
Careful thought and justification should go into any changes.  
The original study protocol from the 2003 study was illustrated in Appendix 1 
and current study protocol in Appendix 2. 
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PART II MATERIAL AND METHODS 
  
  75 
Chapter 9 
9.1 Setting - University College London Hospital (UCLH) 
The studies contained in this thesis was carried out in the UCLH between 
October 2008 and June 2012. Preoperative and postoperative ultrasound 
assessments were performed in the Gynaecology Diagnostic and Outpatient 
Treatment Unit in UCLH.  
UCLH is a teaching hospital and the Women’s Health Department offers 
specialist gynaecology services including gynaecological ultrasound scanning, 
early pregnancy care, urogynaecology, colposcopy, menopause, 
gynaecological oncology, paediatric gynaecology and a specialist endometriosis 
centre. The hospital trust has an annual turnover of more than £769 million, 
employs over 6000 staff and has 665 inpatient beds. It sees over 789,000 
outpatients a year and has around 125,000 inpatient admissions a year. The 
hospital was formed in 1994 and became an NHS foundation Trust in 2004.  
9.2 The UCLH Endometriosis Centre 
The UCLH Endometriosis Centre is a tertiary referral centre for pelvic 
endometriosis and consists of a dynamic multidisciplinary team (including nurse 
specialist, colorectal surgeons, urologists and pain management services) with 
the aim of providing a high-quality and evidence-based care for the treatment of 
women with all grades of endometriosis. 
The surgical treatment of endometriosis was depended on the abnormalities 
found. This included mobilisation of adherent ovaries, removal of ovarian cysts, 
opening the pelvic sidewall peritoneum to dissect the ureters free of 
endometriosis, dissection of obliterated pouch of Douglas. All this was to excise 
superficial and deep endometriotic lesions. 
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9.2.1 Inclusion Criteria: 
Premenopausal women who were 19 years or older were invited to participate 
in our studies. Only women with evidence of severe endometriosis requiring 
extensive dissection of both pelvic side walls and/or rectovaginal space with 
preservation of the ovaries and the uterus were included.  
9.2.2 Exclusion Criteria: 
Women who were unable or unwilling to provide consent and those who were 
unable to tolerate a transvaginal ultrasound scan were excluded from the study. 
We also excluded women who had incomplete excision of endometriosis and 
those who had complicated surgery resulting in unplanned oophorectomy, 
bowel injury or conversion to open surgery.   
9.3 TVS Assessment of Pelvic Endometriosis 
All the ultrasound scans were performed by trained gynaecologists using a 
Voluson E8 ultrasound machine (GE Medical Systems, Milwaukee, WI, USA) 
with a 4-9 MHz probe. All scans were performed with the women in the dorsal 
lithotomy position using a standardised and systematic protocol89. First, the 
uterus was assessed in the transverse and sagittal planes. Next, the ovaries 
were identified and their size was measured in three orthogonal planes.  
Ovarian cysts were diagnosed as endometriomas when they appeared as well-
circumscribed thick-walled cysts that contained homogeneous low-level internal 
echoes (‘ground glass’)193. Measurements were recorded from the inside of the 
cyst wall, again in three orthogonal planes. The average of the three diameters 
(D1+D2+D3)/3 was used for scoring. The adnexa would then be examined for 
the presence of tubal dilatation. If tubal dilatation was present, a score of 16 
was given, in accordance with the revised ASRM endometriosis classification92 
(Chapter 3). 
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Ovarian mobility was assessed by a combination of gentle pressure with the 
vaginal probe and abdominal pressure with the examiner’s free hand, mirroring 
a bimanual examination. The ovary was deemed to be completely free when it 
could be seen sliding across its surrounding structures without any resistance 
(adhesion grade 0). Minimal adhesions were considered to be present when 
less than one third of the surrounding structures could not be separated from 
the ovary with gentle pressure but the ovary could be mobilized from the 
majority (greater than two thirds) of the surrounding structures (adhesion grade 
1). Moderate adhesions were classified when one-third to two-third of ovarian 
mobility was reduced as a result of adhesions with the surrounding structures 
but the structures on one-third of the surface of the ovary slid across it with the 
application of gentle pressure (grade 2). Severe adhesions were characterized 
by fixed ovaries, which could not be mobilized at all with gentle pressure or 
separated from any of the surrounding structures (grade 3). 
If the tubes were dilated, the mobility of the dilated tubes was documented in a 
similar manner. Normal Fallopian tubes are difficult to identify in the absence of 
background fluid in the pelvis and therefore it was not possible to score non-
dilated tubes for adhesions. Filmy adhesions were scored separately from 
dense adhesions of the tubes and ovaries in the ASRM system, however, it can 
be difficult to visualise filmy adhesions on TVS unless there is fluid entrapped 
within the adhesions (‘flapping sail sign’) or if the mobility of the affected organs 
is reduced. 
The presence of adhesions in the pouch of Douglas was assessed next. The 
uterus was gently mobilised by a combination of pressure on the cervix with the 
ultrasound probe alternating with pressure on the fundus from the examiner’s 
free hand on the abdominal wall. The aim was to watch the interface of the 
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posterior uterine serosa and the bowel behind to ensure that the two structures 
were sliding easily across one another. If the two surfaces slide completely free 
of one another, this was assessed as the absence of adhesions. Complete 
obliteration of the pouch of Douglas was assessed as the absence of any 
sliding movements between the two surfaces. Partial obliteration was present if 
there were some adhesions between the bowel and the uterus, but some free 
sliding was seen. Partial obliteration was also present when adnexal structures 
were firmly adherent to the posterior aspect of the uterus but the bowel 
appeared to be free. 
Endometriotic nodules or DIE were typically visualised as stellate hypoechoic or 
isoechogenic solid masses with irregular outer margins87, which were tender on 
palpation and fixed to the surrounding pelvic structures. Nodules were usually 
located in the uterosacral ligaments, adnexa, rectovaginal septum and urinary 
bladder. Endometriotic nodules of the rectosigmoid colon typically appeared as 
hypoechoic thickenings of the bowel muscularis propria, which may protrude 
into the lumen of the bowel194. The presence and largest diameter of any deep 
lesions were documented. 
The above features were documented and scored using the ASRM 
classification92. The score was used to grade the disease as absent (ASRM 
score of 0), minimal (1–5), mild (6–15), moderate (16–40) or severe (>40). In 
the absence of obliteration of the pouch of Douglas, DIE is given a maximum 
score of six on the ASRM classification and we have therefore recorded the 
presence of these lesions separately.  
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9.4 Statistical Considerations 
The background characteristics of patients were presented as means and 
standard deviations for normally distributed data or medians and inter-quartile 
ranges for non-normally distributed continuous variables. The Chi square test 
and Fisher’s exact tests were used to test for statistical significance of 
differences in independent nominal data. The prevalence of ovarian adhesions 
in our cross-over RCT was analysed with a McNemar test. Statistical 
significance was defined using a p-value of less than 0.05. Ninety-five percent 
confidence intervals were calculated for each of the test results to determine the 
precision of the results. 
The level of agreement between ultrasound findings and laparoscopic findings 
was evaluated with Cohen’s kappa, kappa values of 0.81–1.0 being taken to 
indicate very good agreement, 0.61–0.80 good agreement, 0.41–0.60 moderate 
agreement, 0.21–0.40 fair agreement and values ≤ 0.20 poor agreement195.  
Sensitivity, specificity, positive predictive values (PPV), negative predictive 
values (NPV) and positive and negative likelihood ratios (LR+ and LR−) were 
calculated to determine the ability of the tests to predict the presence or 
absence of condition. Tests were considered very useful if LR+ was above 10 
and LR− was below 0.1; moderately useful if LR+ was between 5 and 10 and 
LR− was between 0.1 and 0.2; somewhat useful if LR+ was between 2 and 5 
and LR− was between 0.2 and 0.5; and useless if LR+ was between 1 and 2 
and LR− was between 0.5 and 1196. 
The background characteristics of the patients were age in years, use of 
hormonal contraception (0 = no hormonal treatment, 1 = hormonal treatment) 
and the ASRM endometriosis score. The extent of ovarian adhesion ranges 
from 0 (no adhesions) to 3 (fixed ovaries) and the intensity of pain measured 
  80 
using the visual analogue scale (range from 0 = no pain to 10 = severe pain). 
For statistical analysis, pain score 1-3 was described as mild, 4-7 as moderate 
and 8-10 as severe.   
Statistical analysis was performed by using Stata 10.1 (StataCorp, College 
Station, TX, USA) and IBM SPSS for Macintosh Version 23 (IBM Corp, Armonk, 
NY). 
9.5 Ethical committee approval  
Approval for this study was obtained from the Medical Ethical Committees of the 
University College London Hospital, London, UK. The trial was prospectively 
registered as an International Standard Randomised Clinical Trial (ISRCTN 
24242218). 
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PART IV RESULTS 
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Chapter 10 - Pilot Study - Prevalence of Ovarian Adhesions Following 
Laparoscopic Treatment of Severe Pelvic Endometriosis 
10.1 Introduction 
Prior to the introduction of any medical or surgical intervention to reduce the 
prevalence of postoperative ovarian adhesions in women with severe pelvic 
endometriosis, the prevalence of ovarian adhesions without any intervention 
needs to be determined.  
We carried out this pilot study to determine the prevalence of ovarian adhesions 
on TVS, three months following laparoscopic treatment for severe pelvic 
endometriosis. 
10.2 Methods 
This was a prospective observational study conducted at UCLH and was 
approved by the UCLH Research and Ethics Committee. Women who had 
laparoscopic treatment for severe pelvic endometriosis seen at their three 
months follow up were asked to participate. Suitability for this study was based 
on the operative findings and extent of surgery performed. Women who had 
postoperative ovarian suspension were excluded from the study.  
A TVS was performed at this appointment and the severity of ovarian adhesions 
for each ovary was assessed separately. Assessment was based on the 
mobility of the ovaries on targeted ultrasound palpation. Details of methodology 
was discussed in Chapter 9.3. 
Details of statistical analysis and the criteria used for presentation of data were 
described in Chapter 9.4. 
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10.3 Results  
Between March 2009 and June 2009, 16 premenopausal women were 
identified post laparoscopic treatment for severe endometriosis requiring 
extensive dissection of both pelvic side walls and/or rectovaginal space with 
preservation of the ovaries and uterus. All 16 women consented to have a TVS 
to assess for ovarian adhesions at their three months follow up.  
The mean age was 34.6 years (range 22 to 51). 15 (93.8%) women were 
nulliparous and one (6.3%) multiparous.  
Prior to taking part in the pilot study, six (37.5%) women had no prior surgery, 
nine (56.3%) women had one previous laparoscopic treatment for 
endometriosis and one (6.3%) had two previous surgeries. 
At surgery, all 16 women were found to have severe pelvic endometriosis when 
assessed using the ASRM scoring and their operative findings are summarised 
in Table 1. Histology confirmed the diagnosis of endometriosis in all 16 women. 
At the three months postoperative follow up, one (6.3%) woman was using the 
COCP, one (6.3%) woman was being treated with gonadotrophin-releasing 
hormone agonist, three women had a Mirena IUS in situ and 11 women were 
not on hormonal treatment. 
All postoperative TVS were performed by a single ultrasound observer (WH). 
11/16 women (68.8%) were found to have ovarian adhesions on TVS three 
months post laparoscopic treatment for severe pelvic endometriosis. 4/16 
(25.0%) women had unilateral adhesions, while 7/16 (43.8%) women had 
bilateral adhesions (Figure 7).  
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Table 1 Operative findings at laparoscopy (Pilot study) 
Operative Findings N % 
Right Ovarian Endometriomas 8 50.0 
Left Ovarian Endometriomas 7 43.8 
Pouch of Douglas Adhesions 
    
-        None seen 1 6.3 
-        Partial obliteration 5 31.3 
-        Complete obliteration 10 62.5 
Deep Infiltrating Endometriosis 13 81.3 
 
  
  85 
Figure 7 Prevalence of ovarian adhesion following laparoscopic surgery 
for severe pelvic endometriosis (without ovarian suspension) 
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10.4 Discussion 
Our pilot study has shown that the prevalence of ovarian adhesion rate per 
ovary after laparoscopic surgery for severe endometriosis was 18/32 (56.3%). 
This gave us an approximate adhesion rate of 60% which was used to calculate 
the sample size required for our RCT (Table 2). The intra-class correlation 
coefficient for the presence of adhesions three months after surgery was 
calculated to be 0.52. 
Details of the sample size calculation was discussed in Section 8.10. 
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Table 2 Prevalence of ovarian adhesion on ultrasound following laparoscopic surgery for 
severe endometriosis without ovarian suspension 
 
 
Left ovary 
Total Adhesions present  
(n (%)) 
Adhesions absent  
(n (%)) 
Right 
ovary 
Adhesions present 
(n (%)) 
7 (43.8) 2 (12.5) 9 (56.3) 
Adhesions absent  
(n (%)) 
2 (12.5) 5 (31.3) 7 (43.8) 
Total 9 (56.3) 7 (43.8) 16 (100) 
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Chapter 11 - Does ovarian suspension following laparoscopic surgery for 
endometriosis reduce postoperative adhesions? An RCT 
11.1 Introduction 
A wide range of interventions has been tried in order to reduce postoperative 
pelvic adhesions, but none has gained wide acceptance. Intra-operative 
suspension of the ovaries to the anterior abdominal wall is often used to 
facilitate ovarian retraction during surgery for severe pelvic endometriosis185. 
Observational studies have suggested that temporary postoperative ovarian 
suspension may reduce the frequency of postoperative pelvic adhesions186,187. 
The aim of this RCT was to assess the effect of temporary ovarian suspension 
following laparoscopic surgery for severe pelvic endometriosis on the 
prevalence of postoperative ovarian adhesions. 
11.2 Methods 
This was a prospective double blind cross-over comparison RCT conducted at 
UCLH. Premenopausal women diagnosed with severe pelvic endometriosis at 
their preoperative TVS were invited to participate in the study. Suitability for 
randomisation was confirmed at surgery. Details of inclusion and exclusion 
criteria were discussed in Chapter 9.   
11.2.1 Intervention 
During laparoscopic treatment of severe endometriosis, both ovaries were 
routinely suspended to the anterior abdominal wall using a 2/0 Prolene suture 
(Ethicon Inc., Somerville, New Jersey, USA) which was brought out onto the 
skin and secured using a fine haemostat or ‘mosquito’ clip during surgery. This 
was performed to facilitate access to the pelvic side walls during operation and 
a complete excision of the disease (Figure 9 and 10). 
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Figure 8 Ovarian suspension of both ovaries at laparoscopy to improve access to Pouch of Douglas  
diseased with endometriosis 
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Figure 9 Ovarian suspension stitch through a left ovary 
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At the end of the operation, women were randomised to have one ovary 
suspended for 36 to 48 hours postoperatively. One of the ovarian suspension 
sutures was cut to allow that ovary to fall back into the lesser pelvis. A new 
transabdominal suture was then re-inserted at the same site to act as a placebo 
stitch. The pneumoperitoneum was deflated and the Prolene suture of the 
suspended ovary was tightened with a surgical knot placed over the skin to 
secure the ovary to the abdominal wall. This was done to ensure that the 
suspended ovary was lifted as far away from the pelvic side wall as possible. A 
surgical knot was secured with the space of a straight surgical suture cutting 
scissors between the skin and the knot to allow easier removal of the suture 
and reduce patient discomfort. All randomised patients therefore had two 
abdominal sutures of similar length. The patient and clinical staff were blinded 
to the randomisation. The only members of staff who were aware of the site of 
ovarian suspension were the surgeons who were under strict instructions not to 
discuss individual patient’s treatment allocations with the patient or any other 
members of the clinical and nursing staff. Both sutures were cut 36 to 48 hours 
after surgery by a ward nurse who was not part of the operating or research 
team and who was blinded to the ovarian suspension site.  
11.2.2 Follow-up 
Three months after ovarian suspension, all women were scheduled for a TVS to 
assess ovarian mobility. Ovarian adhesions were diagnosed by the presence of 
restricted ovarian mobility on targeted palpation using TVS as described in 
Chapter 9.3. The ultrasound operators were blinded to the details of the 
women’s randomisation allocation. A CONSORT diagram was produced to 
show the flow of patients through the RCT (Figure 10). 
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Figure 10 CONSORT flow diagram of patients through the RCT 
 
 
RCT, Randomised controlled trial; TVS, transvaginal ultrasound scan 
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11.2.3 Outcome measures 
The primary outcome was the prevalence of ovarian adhesions on TVS after 
surgery. Secondary outcomes were the extent of ovarian adhesions, the effects 
of hormonal treatment and cystectomies on adhesion rates and changes in pain 
symptoms. 
11.2.4 Sample size 
The sample size calculation was based on the findings of the earlier pilot work. 
Prevalence of ovarian adhesions for each ovary was 18/32 (56.3%) and this 
was approximated to 60%. Details of the sample size calculation was discussed 
in Section 8.10. 
11.2.5 Randomisation 
Participants were randomised to unilateral suspension of either right or left 
ovary. Block randomisation was used with three varying block sizes of minimum 
size four. Details of the randomisation schedule was discussed in Section 8.11.  
11.2.6 Statistical analysis 
Details of statistical analysis and the criteria used for presentation of data were 
described earlier (Chapter 9.4). 
11.3 Results  
Between November 2009 and June 2012, 122 premenopausal women were 
diagnosed with severe pelvic endometriosis on preoperative transvaginal 
ultrasound scan and they were invited to join the study. Six (4.9%) women 
declined the study and three (2.5%) women did not have surgery. 58 women 
did not fulfil inclusion criteria for the following reasons: 15 (25.9%) women 
received only partial treatment of endometriosis, 11 (19.0%) women had bowel 
surgery, nine (15.5%) had ‘two-stage’ procedures, another nine (15.5%) did not 
have bilateral severe pelvic endometriosis at surgery, five (8.6%) had 
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oophorectomies, another five (8.6%) had hysterectomies and four (6.9%) had 
laparotomies.  
55 women fulfilled the inclusion criteria for randomisation and underwent 
unilateral ovarian suspension. Three women were excluded from final data 
analysis, as they did not attend for a postoperative ultrasound scan: one 
became pregnant, another was lost to follow up and the third woman suffered a 
large bowel injury diagnosed postoperatively for which she required further 
surgery and repair at her local hospital. The research and ethics committee was 
informed of this complication and a serious adverse event (SAE) notice was 
filed. Therefore, 52 women were included in the final analysis (Figure 10). 
All 52 women were pre-menopausal and their mean age was 32.6 years (range 
22-46). 42 (80.8%) women were nulliparous, three (5.8%) were primiparous and 
seven (13.5%) multiparous.  
Prior to taking part in the trial, 21 (40.4%) women had one previous 
laparoscopic treatment for endometriosis, four (7.7%) had two, two (3.9%) had 
three and one (1.9%) woman had four previous laparoscopic surgeries.   
All participants were asked about symptoms of endometriosis including 
dysmenorrhoea, deep dyspareunia, chronic pelvic pain and dyschezia. They 
were also asked about menstrual disorders and history of subfertility. One 
(1.9%) woman presented with a single symptom. Six (11.5%) women had two 
symptoms, 12 (23.1%) women had three symptoms, 20 (38.5%) women had 
four symptoms, 12 (23.1%) women had five symptoms and one (1.9%) woman 
had six symptoms (Table 3).  
At presentation, 38 (73.1%) women were not on hormonal treatment, 6 (11.5%) 
women were using COCP, four (7.7%) women were being treated with 
gonadotrophin-releasing hormone agonist, three (5.8%) women were using a 
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progesterone-only pill and the remaining one (1.9%) woman had a Mirena IUS 
in situ.  
The median interval between preoperative scan assessment and ovarian 
suspension was 166 [interquartile range (IQR) 117-243] days. The median 
interval between the first and second stage operation was 161.5 (IQR 108-229) 
days.  
At surgery, all 52 women were found to have severe pelvic endometriosis when 
assessed using the ASRM scoring and their operative findings were 
summarised in Table 4. Postoperative TVS was performed to assess ovarian 
mobility after surgery and ovarian suspension. The median interval between 
ovarian suspension and postoperative scan was 99 days (IQR 68-114).  
 
 
.
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Table 3 Pre and postoperative symptoms 
Symptoms of 
endometriosis 
Preoperative symptoms  
(n (%)) 
Postoperative symptoms  
(n (%)) 
OR (95% CI) P-value 
Dysmenorrhoea 39 (75.0) 11 (21.2) 0.03 (0.00-0.21) <0.001 
Deep dyspareunia 26 (50.0) 7 (13.5) 0.10 (0.01-0.39) <0.001 
Dyschezia 30 (57.7) 5 (9.6) 0.0 (0.00-0.16) <0.01 
Pelvic Pain 43 (82.7) 26 (50.0) 0.06 (0.00-0.35) <0.001 
  
Mean VAS 5.79 1.98   < 0.001 
  
  
Pain severity   
None (VAS = 0) 9 (17.3) 26 (50.0) 
Mild (VAS 1-3) 7 (13.5) 16 (30.8) 
Moderate (VAS 4-7) 13 (25.0) 8 (15.4) 
Severe (VAS 8-10) 23 (44.2) 2 (3.9) 
 
VAS, visual analogue scale; OR, odds ratio 
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Table 4 Operative findings at laparoscopy (RCT) 
Operative Findings N % 95% CI 
Right Ovarian Endometriomas 25 48.1 34.5-61.7 
Left Ovarian Endometriomas 24 46.2 32.6-59.7 
Hydrosalpinges 13 25 13.2-36.8 
Pouch of Douglas Adhesions       
-        None seen 1 1.9 0.0-5.7 
-        Partial obliteration 8 15.4 5.6-25.2 
-        Complete obliteration 43 82.7 72.4-93.0 
Deep Infiltrating Endometriosis 45 86.5 77.3-95.8 
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11.3.1 Ultrasound Observers 
Ultrasound observer A (WH, candidate) was a clinical fellow in gynaecology 
who had performed more than 3000 TVS on women with gynaecological 
conditions in the three years of fellowship. Ultrasound observer B (NA) was a 
senior consultant in the Gynaecology Diagnostic Unit who had undertaken over 
10000 TVS for over 10 years and observer C (KP) another clinical fellow who 
had performed about 1000 TVS in her first year of fellowship.  
Of the 55 women randomised during the trial, four women did not have 
preoperative ultrasound assessment in our department because a diagnosis of 
severe endometriosis was made at laparoscopy prior to their referral to our Unit. 
Five observers performed all the preoperative ultrasound assessments in the 
remaining 51 women. Observer A assessed 33 women (64.7%), observer B six 
(11.8%) and observer C five 5/51 (9.8). The remaining scans were completed 
by two other consultants from the gynaecology unit, DJ four (7.8%) and RS 
three (5.9%).  
Postoperatively, 52 women were followed up for the trial as described. Three 
observers completed all the postoperative ultrasound assessments. Observer A 
assessed 33 women (63.5%), observer B 11 (21.2%) and observer C eight 
(15.4%). A detailed breakdown of the number of scans performed by each 
observer was summarised in Table 5.  
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Table 5 Number of scans performed scanned by each observer 
Observer Preoperative Scans (n (%)) Postoperative scans (n (%)) 
A 33/51 (64.7)  33/52 (63.5) 
B  6/51 (11.8)  8/52 (15.4) 
C  5/51 (9.8)  11/52 (21.2) 
Others  7/51 (13.7)  0 
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11.3.2 Accuracy of Preoperative TVS for the Diagnosis of Endometriosis  
To assess the accuracy of the three postoperative observers, a comparison of 
their preoperative ultrasound assessments was made to the laparoscopic 
findings.  
Table 6 shows the overall Kappa agreement between the preoperative 
ultrasound findings and laparoscopic findings during surgery for assessing the 
individual features of severe endometriosis.  
Table 7 shows the inter-observer agreement between each of the observers 
and laparoscopic findings for the same features of endometriosis. There was a 
good level of agreement, individually and cumulatively, with findings at surgery. 
There was no significant difference in the prevalence of endometriomas, 
ovarian adhesions, pouch of Douglas obliteration and endometriotic nodules 
assessed by each of the three observers.  
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Table 6 Preoperative ultrasound Kappa agreement between all observers and laparoscopic findings 
 
Features Prevalence (n (%)) 
All observers on TVS and 
Laparoscopy, Cohen’s kappa (SE) 
Endometriomas 48/102 (47.1) 0.90 (0.04) 
Ovarian adhesions (Any) 81/102 (79.4) 0.76 (0.08) 
POD Obliteration (partial or complete) 46/51 (90.2) 0.74 (0.14) 
Endometriotic nodules 39/51 (76.5) 0.72 (0.10) 
 
Total number of patients who had preoperative scans = 51 
TVS, transvaginal ultrasound scans 
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Table 7 Preoperative ultrasound Kappa agreement between observer A, B, C and laparoscopic findings 
 
Features 
Prevalence 
(n (%)) 
Observer A on TVS 
and Laparoscopy, 
Cohen’s kappa (SE) 
Prevalence 
(n (%)) 
Observer B on TVS 
and Laparoscopy, 
Cohen’s kappa (SE) 
Prevalence 
(n (%)) 
Observer C on TVS 
and Laparoscopy, 
Cohen’s kappa (SE) 
P - value 
Endometriomas 36/66 (54.5) 0.88 (0.06) 4/12 (33.3) 1.00 4/10 (40.0) 1.00 0.32 
Ovarian adhesions 
(any) 
55/66 (83.3) 0.70 (0.12) 7/12 (58.3) 0.64 (0.22) 8/10 (80.0) 1.0 (0.00) 0.13 
POD obliteration 
(partial or complete) 
30/33 (90.9) 0.84 (0.16) 4/6 (66.7) 0.67 (0.29) 5/5 (100.0) - 0.22 
Endometriotic 
nodules 
25/33 (75.8) 0.72 (0.13) 4/6 (66.7) 0.67 (0.29) 3/5 (60.0) 1.0 (0.00) 0.62 
 
 Total number of patients who had preoperative ultrasound by Observer 1, 2 and 3 = 44 (7 patients were scanned by two other observers) 
TVS, transvaginal ultrasound scans 
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Table 8 shows the sensitivity, specificity, positive and negative predictive 
values, likelihood ratios and area under the receiver–operating characteristics 
curve for each observers for assessing the individual features of severe 
endometriosis with respect to the findings on laparoscopy. There were good 
levels of detection rates for endometriomas, ovarian adhesions, pouch of 
Douglas obliterations and endometriotic nodules.   
Fisher’s exact test was used to compare the accuracy of the preoperative 
ultrasound findings between the three observers. An analysis was considered 
accurate if adhesions were detection preoperatively and confirmed operatively. 
There was no statistically significant difference between the three observers in 
terms of their accuracy in detecting adhesions for either ovary or when data 
from both ovaries were analysed. A summary of the analysis was illustrated in 
Table 9.  
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Table 8 Accuracy of preoperative ultrasound when compared to operative findings 
Features Ob 
Prev 
(%) 
Sensitivity  
(% (95%CI)) 
Specificity   
(% (95%CI)) 
PPV (% (95%CI)) NPV (% (95%CI)) LR+ (% (95%CI)) LR- (% (95%CI)) AUC (% (95%CI)) 
Endometriomas 
All 47.1 91.7 (80.0-97.7) 98.2 (90.1-100.0) 97.8 (88.2-99.9) 93.0 (83.0-98.1) 49.50 (7.09-345.71) 0.08 (0.03-0.22) 0.949 (0.899-1.000) 
A 54.5 91.7 (77.5-98.3) 96.7 (82.8-99.9) 97.1 (84.7-99.9) 90.6 (75.0-98.0) 27.50 (3.99-189.38) 0.09 (0.03-0.26) 0.942 (0.877-1.000) 
B 33.3 100.0 (39.8-100.0) 100.0 (63.1-100.0) 100.0 (39.8-100.0) 100.0 (63.1-100.0) - - 1.000 
C 40.0 100.0 (39.8-100.0) 100.0 (54.1-100.0) 100.0 (39.8-100.0) 100.0 (54.1-100.0) - - 1.000 
Overall Ovarian 
Adhesions 
All 79.4 95.1 (87.8-98.6) 81.0 (58.1-94.6) 95.1 (87.8-98.6) 81.0 (58.1-94.6) 4.99 (2.06-12.07) 0.06 (0.02-0.16) 0.880 (0.777-0.983) 
A 83.3 92.7 (82.4-98.0) 81.8 (48.2-97.7) 96.2 (87.0-99.5) 69.2 (38.6-90.0) 5.1 (1.5-17.9) 0.09 (0.03-0.24) 0.873 (0.733-1.000) 
B 58.3 100.0 (59.0-100.0) 60.0 (14.7-94.7) 77.8 (40.0-97.2) 100.0 (29.2-100.0) 2.50 (0.85-7.31) - 0.800 (0.509-1.000) 
C 80.0 100.0 (15.8-100.0) 100.0 (63.1-100) 100.0 (15.8-100.0) 100.0 (63.1-100) - - 1.000 
POD Obliteration 
(partial and 
complete) 
All 90.2 93.5 (82.1-98.6) 100.0 (47.8-100.0) 100.0 (91.8-100.0) 62.5 (24.5-91.5) - 0.07 (0.02-0.19) 0.967 (0.921-1.000) 
A 90.9 96.7 (82.8-99.9) 100.0 (29.2-100.0) 100.0 (88.1-100.0) 75.0 (19.4-99.4) - 0.03 (0.00-0.23) 0.983 (0.942-1.000) 
B 66.7 75.0 (19.4-99.4) 100.0 (15.8-100.0) 100.0 (29.2-100.0) 66.7 (9.4-99.2) - 0.25 (0.05-1.36) 0.875 (0.571-1.000) 
C 100 100.0 (47.8-100.0) - 100.0 (47.8-100.0) - 1.00 - - 
Endometriotic 
Nodules 
All 76.5 84.6 (69.6-94.1) 100.0 (73.5-100.0) 100.0 (89.4-100.0) 66.7 (41.0-86.7) - 0.15 (0.07-0.32) 0.923 (0.850-0.996) 
A 75.8 84.0 (63.9-95.9) 100.0 (63.1-100.0) 100.0 (83.9-100.0) 66.7 (34.9-90.1) - 0.16 (0.07-0.39) 0.920 (0.827-1.000) 
B 66.7 75.0 (19.4-99.4) 100.0 (15.8-100.0) 100.0 (29.2-100.0) 66.7 (9.4-99.2) - 0.25 (0.05-1.36) 0.875 (0.571-1.000) 
C 60.0 100.0 (29.2-100.0) 100.0 (15.8-100.0) 100.0 (29.2-100.0) 100.0 (15.8-100.0) - - 1.000 
Ob, observers; Prev, prevalence; PPV, positive predictive value; NPV, negative predictive value; LR−, negative likelihood ratio; LR+, positive 
likelihood ratio; AUC, area under receiver–operating characteristics curve 
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Table 9 Accuracy of preoperative ultrasound diagnosis of ovarian adhesions per observer 
 
Observers 
Accurate preoperative ultrasound diagnosis 
of ovarian adhesions confirmed at 
laparoscopy (n (%)) 
P-value 
Observer A 60/66 (90.1) 
0.56 Observer B 10/12 (83.3) 
Observer C 10/10 (100.0) 
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11.4 Primary Outcome of Ovarian Suspension 
The primary outcome was to assess the prevalence of ovarian adhesions on 
ultrasound after surgery. Of the 52 women who had postoperative follow up 
scan, 25 women had left ovarian suspension while 27 women had right ovarian 
suspension. On examination, 38.5% (20/52) of suspended ovaries had 
postoperative adhesions on scan when compared with 51.9% (27/52) of 
unsuspended ovaries (Table 10). A McNemar’s test found no significant 
difference between the two groups [OR 0.56 (95% CI 0.22-1.35)] (P=0.23).  
 
11.4.1 Primary Outcome Adjusted for Multiple Observers 
A sensitivity analysis was performed using multilevel logistic regression to 
account for the differences between the three observers who performed the 
postoperative ultrasound assessment. Two-level models were used with 
measurements from individual ovaries (Table 11). All three analyses gave 
similar odds ratios. The regression analysis with and without adjustments for 
observer differences gave equivalent results (P=0.17), which suggest that the 
results were not influenced by the presence of more than one ultrasound 
observer. 
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Table 10 Absence of adhesions (Grade 0) vs. any adhesions (Grade 1-3) by treatment type 
  
Unsuspended Ovaries 
  
Absence of ovarian 
adhesion 
Presence of any 
ovarian adhesions 
Total 
Su
sp
en
d
ed
 O
va
ri
es
 Absence of 
ovarian adhesion 
16 (30.8%) 16 (30.8%) 32 (61.5%) 
Presence of any 
ovarian adhesions 
9 (17.3%) 11 (21.2%) 20 (38.5%) 
Total 25 (48.1%) 27 (51.9%) 52 (100%) 
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Table 11 Prevalence of ovarian adhesions after ovarian suspension adjusted for the presence of multiple observers 
 
Analysis method Adjustments Odds ratio (95% CI) (*) P-value 
McNemar test None 0.56 (0.22-1.35) 0.23 
Logistic regression 
None 0.56 (0.25-1.27) 0.17 
Observer 0.56 (0.25-1.27) 0.17 
 
(*) Odds ratio expressed as odds of adhesions in suspended ovary relative to unsuspended 
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11.4.2 Primary Outcome for Each Observer 
A subgroup analyses was performed to examine the treatment differences 
(suspended vs. unsuspended ovary) separately for each of the three observers. 
As with the analysis of all patients combined, the analysis was performed using 
the McNemar test. The results of the analysis were summarised in Table 12.   
The analysis suggested that when the results from observer A were considered 
alone, there was a significant difference in outcome between the treatment 
groups. Adhesions were significantly less common in the suspended group, 
occurring in 33% of patients, when compared to 64% in unsuspended ovaries 
(p=0.02).  
There was no difference in adhesion detection for observer B or C. It was noted 
that the numbers of patients were smaller for these two observers. 
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Table 12 Prevalence of postoperative ovarian adhesions per observer 
 
 Prevalence of postoperative ovarian adhesions   
Observer Unsuspended ovaries (n (%)) Suspended ovaries (n (%)) 
Odds ratio  
(95% CI) 
P-value 
Observer A 21/33 (63.6) 11/33 (33.3) 0.23 (0.04-0.84) 0.02 
Observer B 2/8 (25.0) 4/8 (50.0) 0.33 (0.04 – 2.76) 0.5 
Observer C 4/11 (36.3) 5/11 (45.5) 1.33 (0.23-9.10) 1 
 
(*) Odds ratio expressed as odds of adhesions in suspended ovary relative to unsuspended ovary 
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11.4.3 Primary Outcome Between Observers  
Additional analyses were performed to examine the differences between the 
three observers in terms of detection of adhesions on postoperative ultrasound 
Table 13. There was no significant difference between the three observers for 
the suspended ovary. 
In the unsuspended group, although there appeared to be some suggestion of a 
difference between observers in terms of detection of adhesions, this difference 
was not statistically significant.  
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Table 13 Prevalence of ovarian adhesions for each observer according to treatment groups 
 
Ovary Observers Prevalence of ovarian adhesions (n (%)) p-value 
Suspended 
Observer A 11/33 (33.3) 
0.55 Observer B 4/8 (50.0) 
Observer C 5/11 (45.5) 
Unsuspended 
Observer A 21/33 (63.6) 
0.10 Observer B 2/8 (25.0) 
Observer C 4/11 (36.4) 
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11.5 Secondary Outcomes  
11.5.1 Severity of Ovarian Adhesions 
The primary outcome was the presence of ovarian adhesions of any degree 
diagnosed with TVS three months after surgery. In secondary outcomes, two 
additional analyses were considered, namely the presence of either moderate 
or severe ovarian adhesions (grade 2 or 3 adhesions) and the presence of 
severe adhesions only (grade 3 adhesions) at the three months’ post-operative 
ultrasound. 
When moderate to severe adhesions were considered, 9.6% (5/52) of 
suspended ovaries had moderate-severe adhesions when compared with 
19.2% (10/52) of unsuspended ovaries [OR 0.38 (95% CI 0.06-1.56)] (P=0.23) 
(Table 14). When only fixed ovaries or severe adhesions were considered, 
7.7% (4/52) of suspended ovaries had fixed ovaries when compared with 13.5% 
(7/52) of unsuspended ovaries [OR 0.40 (95% CI 0.04-2.44)] (P=0.45) (Table 
15). Overall, there was no statistically significant difference in the treatment 
groups when varying degrees of adhesions were compared.  
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Table 14 None - mild adhesions (Grade 0 - 1) vs. moderate - severe adhesions (Grade 2-3) by treatment type 
 
  
Unsuspended ovaries 
  
None to mild 
adhesions 
Moderate to 
severe adhesions 
Total 
Su
sp
en
d
ed
 o
va
ri
es
 None to mild 
adhesions 
39 (75.0%) 8 (15.4%) 47 (90.4%) 
Moderate to 
severe adhesions 
3 (5.8%) 2 (3.8%) 5 (9.6%) 
Total 42 (80.8%) 10 (19.2%) 52 (100%) 
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Table 15 None - moderate adhesions (Grade 0-2) vs. severe adhesions (Grade 3) by treatment type 
 
  
Unsuspended ovaries 
  
None to moderate 
adhesions 
Severe adhesions Total 
Su
sp
en
d
ed
 o
va
ri
es
 None to moderate 
adhesions 
43 (82.7%) 5 (9.6%) 48 (92.3%) 
Severe adhesions 2 (3.8%) 2 (3.8%) 4 (7.7%) 
Total 45 (86.5%) 7 (13.5%) 52 (100%) 
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11.5.2 Severity of Ovarian Adhesions Adjusted for Multiple Observers  
The original analysis, which was assessed using a McNemar test, was repeated 
using multilevel logistic regression to evaluate for any multiple observer effects 
(Table 16). As observer B did not detect any moderate or severe adhesions 
(grade 2 or 3) in the postoperative scans, the results for observers KP and NA 
were combined for the purposes of this analysis.  
The analysis suggested that for both the presence of moderate or severe 
adhesions and severe adhesions only, all three analyses gave similar odds 
ratios with no significant differences. The unadjusted results using logistic 
regression produced slightly narrower confidence intervals and smaller p-values 
than those obtained using the McNemar test, which is not uncommon when 
different methods of analysis were employed. The regression analysis that 
adjusted for the observer differences produced equivalent results to those 
without adjustment for observers.  
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Table 16 The prevalence of moderate-severe adhesions and severe adhesions after ovarian suspension  
adjusted for the presence of multiple observers 
 
Adhesion type 
Analysis 
method 
Adjustments Odds ratio (95% CI) (*) P-value 
Presence of 
moderate to severe 
adhesions 
McNemar test None 0.38 (0.06-1.56) 0.23 
Logistic 
regression 
None 0.37 (0.09-1.41) 0.15 
Observer 0.38 (0.10-1.41) 0.15 
Presence of severe 
adhesions only 
McNemar test None 0.40 (0.04-2.44) 0.45 
Logistic 
regression 
None 0.39 (0.07-2.12) 0.28 
Observer 0.40 (0.08-2.07) 0.28 
 
(*) Odds ratio expressed as odds of adhesions in suspended ovary relative to unsuspended 
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11.5.3 Severity of Ovarian Adhesions for Each Observer 
A subgroup analysis was performed using the McNemar test to examine the 
prevalence of ovarian adhesions according to the treatment groups, with or 
without ovarian suspension, for each of the three observers. The results were 
summarised in Table 17.  
The results suggested that there were no significant differences between 
suspended and unsuspended ovaries for any of the three observers for either 
treatment groups. 
 
11.5.4 Severity of Ovarian Adhesions Between Observers 
Additional analyses were performed using the Fisher’s exact test to examine the 
differences between the three observers in their diagnosis of moderate or 
severe adhesions and severe adhesions only at the three months’ post-
operative ultrasound (Table 18).  
There was no significant difference between the three observers in their 
diagnosis of adhesions in either treatment groups. 
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Table 17 The presence of moderate-severe adhesions and severe adhesions per observer 
 
Severity of adhesions Observers 
Prevalence of ovarian 
adhesions in unsuspended 
ovaries (n (%)) 
Prevalence of ovarian 
adhesions in suspended 
ovaries (n (%)) 
Odds ratios 
(95% CI) (*) 
P-value 
Moderate to severe 
adhesions 
Observer A 9/33 (27.3) 5/33 (15.2) 0.43 (0.07, 1.88) 0.34 
Observer B 0/8 (0.0) 0/8 (0.0) (#) 1 
Observer C 1/11 (9.1) 0/11 (0.0) (#) 1 
Severe adhesions only 
Observer A 6/33 (18%) 4/33 (12%) 0.50 (0.05, 3.49) 0.69 
Observer B 0/8 (0.0) 0/8 (0.0) (#) 1 
Observer C 1/11 (9.1) 0/11 (0.0) (#) 1 
 
(*) Odds ratio expressed as odds of adhesions in suspended ovary relative to unsuspended 
(#) Unable to calculate odds ratios due to the one of the number of patients in one of the discordant pairs being zero 
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Table 18 The presence of moderate to severe adhesions and severe adhesions per observer 
 
Severity of adhesions 
Treatment 
groups 
Observers Prevalence of ovarian adhesions (n (%)) P-value 
Moderate to severe 
adhesions 
Suspended 
Observer A 5/33 (15.2) 
0.40 Observer B 0/8 (0.0) 
Observer C 0/11 (0.0) 
Unsuspended 
Observer A 9/33 (27.3) 
0.23 Observer B 0/8 (0.0) 
Observer C 1/11 (9.1) 
Severe adhesions only 
Suspended 
Observer A 4/33 (12.1) 
0.45 Observer B 0/8 (0.0) 
Observer C 0/0 (0.0) 
Unsuspended 
Observer A 6/33 (18.2) 
0.52 Observer B 0/8 (0.0) 
Observer C 1/11 (9.1) 
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11.5.5 Postoperative Hormonal Treatments  
Postoperatively, each woman was also assessed for postoperative symptoms 
(Table 3) and the use of hormonal treatments. There was a general reduction in 
the symptoms of endometriosis after surgery. However, an additional 17 
(32.7%) women were given hormonal treatment after surgery, which may have 
contributed to the reduction in symptoms.  
At the three months’ post-operative follow up, 19 (36.5%) women had a Mirena 
IUS inserted, five (9.6%) women were taking a COCP, four (7.7%) were treated 
with gonadotrophin-releasing hormone agonist, three (5.8%) used a 
progesterone-only pill and 21 (40.4%) women did not use any hormonal 
treatments.  
There was no significant difference in the rates of ovarian adhesion when 
patients who used postoperative hormonal treatments were compared to 
patients not on treatment (Fisher’s exact p = 0.85). Similar results were 
obtained when patients were subdivided into their treatment groups (Table 19). 
A comparison of ovaries exposed to different hormonal treatments did not 
suggest any difference between the types of hormones used (Fisher’s exact p = 
0.07) (Table 20).  
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Table 19 The prevalence of ovarian adhesions according to the use of hormonal treatments by treatment groups 
 
Treatment groups 
Postoperative use of 
hormonal treatment 
Prevalence of ovarian 
adhesions (n (%)) 
p-value 
Suspended ovaries 
Hormonal treatment 15/ 31 (48.3) 
0.57 
No hormonal 
treatment 
8/ 21 (38.1) 
Unsuspended 
ovaries 
Hormonal treatment 14/ 31 (45.1) 
1.00 
No hormonal 
treatment 
10/ 21 (47.6) 
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Table 20 Ovarian adhesion rates according to the type of hormonal treatment 
Postoperative 
hormonal treatment 
Presence of postoperative 
adhesions (n (%)) 
p-value 
Mirena IUS 14/38 (36.8) 
0.07 POP 5/6 (83.3) 
COCP 6/10 (60.0) 
 
IUS, intrauterine system 
 
 
 
11.5.6 Ovarian Cystectomies 
At laparoscopy, nine (17.3%) women had right ovarian cystectomies, seven 
(13.5%) had left ovarian cystectomies and 16 (30.8%) had bilateral ovarian 
cystectomies performed.  
Additional analysis was performed to assess if having an ovarian cystectomy 
during their primary surgery had additional effects on the presence of ovarian 
adhesions at the three months postoperative follow up. There was also no 
significant difference in the postoperative adhesion rates on the same side 
when an ovarian cystectomy was performed on the left (Fisher’s exact p = 0.79) 
or right ovary (Fisher’s exact p = 0.16). 
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11.6 Discussion 
Our RCT has shown that temporary unilateral ovarian suspension for 36-48 
hours in premenopausal women with stage IV pelvic endometriosis did not 
result in a significant reduction of postoperative adhesions when compared with 
the unsuspended side.  
There are several possible explanations for our findings. We suspended ovaries 
for only 36 to 48 hours which may have contributed to the negative result. Some 
may consider the relatively short period of postoperative ovarian suspension a 
weakness. We decided on this length of suspension after taking into 
consideration a methodologically robust study by Harris et al.,160 who used an 
animal model to show that susceptibility for adhesion formation was significantly 
reduced or eliminated when separation of peritoneal surfaces was maintained 
for at least 36 hours following peritoneal injury. Other authors have suggested 
that peritoneal healing can take up to five days to complete158,159. In addition, it 
has been hypothesised that the persistent presence of blood in the peritoneal 
cavity following surgery may stimulate adhesion formation197. However the 
study by Harris et al.160 was methodologically stronger and its main aim was to 
evaluate the question of minimal duration of intervention for adhesion 
prevention. We did consider suspending the ovaries following laparoscopic 
surgery for longer than 36 hours, but we were concerned about the risk of 
serious complications such as small bowel strangulation. This complication 
needs immediate correction and for that reason we decided against discharging 
patients from hospital with the suspension sutures in situ.  
In a retrospective review of 218 patients who had extensive surgery for severe 
endometriosis with transient ovarian suspension for five days, two complications 
(0.7%) were reported198. One patient had an ovarian abscess drained via a 
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posterior colpotomy eight days after her primary surgery. The second patient 
had hemoperitoneum caused by the bleeding from the suspension site on the 
ovary which required emergency laparoscopy on the first post-operative day.  
Our surgical team had previously encountered a case of acute small bowel 
obstruction following a similar suspension procedure which required immediate 
release of the suspension suture (data on file). By limiting the duration of 
ovarian suspension in our study, we shortened the women’s postoperative in-
patient stay, minimised their social disruption and avoided increasing their 
treatment costs.  
Ouahba el al.187 suspended 12 ovaries in eight women for four days following 
extensive surgery for severe pelvic endometriosis. A second-look laparoscopy 
performed five months after the first procedure found significant ovarian 
adhesions in 33% of cases. This was only a slight improvement when compared 
to the 38% adhesions rate in our study. This would suggest that a longer 
duration of suspension may not actually lead to better surgical outcomes. 
Our results are in contrast to a small study by Abuzeid et al.,186 which 
suggested a reduction in postoperative ovarian adhesions with temporary 
ovarian suspension. The authors reported findings at second-look laparoscopy 
in five women who had ovaries suspended for five to seven days following 
laparoscopic surgery for stage 3 or 4 pelvic endometriosis. They found mild 
ovarian adhesions in one woman (20%) whilst the remaining four women were 
completely free of adhesions. However, the number of patients in this study was 
very small, whereas, we recruited a sufficient number of patients to detect 
significant differences between suspended and unsuspended ovaries.  
The main strength of our study was our trial design which was a prospective 
placebo-controlled randomised trial. We opted for a cross-over study design, 
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which is considered to be particularly powerful and free from disadvantages 
which may affect the quality of parallel group trials. Although the surgeons were 
aware of the side of ovarian suspension, the patients and ultrasound operators 
were blinded to randomisation. A dummy abdominal suture was inserted on the 
site of the unsuspended ovary and the sutures were removed by a ward nurse 
who was not part of the trial. Both the surgeons and ward staff were instructed 
not to discuss possible ovarian suspension site with the patient after surgery or 
during the time of suture removal. It is therefore very unlikely that our results 
were influenced by bias.  
Ideally, any outcome measure in a clinical trial should be precise and 
reproducible. Inter-observer variability in clinical trials is a potential source of 
bias and should be minimised. If possible, all subjective and objective 
assessments should be performed by the same observer, but this is rarely 
achievable. In our trial, the postoperative TVS assessments were performed by 
three observers with Observer A (the candidate) performing the majority of 
ultrasound assessments (64.7% of preoperative and 63.5% of postoperative 
scans). The effect of multiple observers was not considered when the sample 
size was calculated. We assessed the performance of the ultrasound operators 
in our study by comparing preoperative ultrasound findings with the operative 
findings. For each observer, the best agreement was with the diagnosis of 
endometriomas, but there was also a good level of agreement for ovarian 
adhesions, pouch of Douglas obliteration and endometriotic nodules. There was 
no significant difference between three observers in the accuracy of 
preoperative ultrasound diagnosis of ovarian adhesions (p = 0.56). It is 
therefore unlikely that the use of multiple observers was a source of bias.  
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Further analysis was carried out to evaluate agreement between three 
observers in the detection and classification of severity of pelvic adhesions 
using multilevel logistic regression. We found no significant difference between 
the observers. A subgroup analysis of the primary outcome for each observer 
did suggest a statistical difference between the suspended and unsuspended 
ovaries when the results from observer A was considered alone (p=0.02). 
Adhesions were less common in the suspended group, occurring in only 11 out 
of 33 ovaries when compared to 21 ovaries in the unsuspended group. This is 
likely to be a chance occurrence due to the small number evaluated. There was 
no significant difference in the proportion of adhesions between suspended and 
unsuspended ovaries in women who were examined by observer B and C. They 
both reported a slightly higher prevalence of ovarian adhesions in the 
suspended ovaries. This result is unlikely to be influenced by the experience of 
the operators as less experienced examiners are more likely to miss rather than 
over diagnose pelvic adhesions.  
The primary outcome in our study was the presence of any ovarian adhesions. 
However, the presence of severe adhesions may be more clinically relevant 
than mild or moderate adhesions. We therefore carried out additional analysis 
to examine differences in the prevalence of moderate and severe adhesions 
and we found no significant results (Table 16).  
In our study, we decided to use ultrasound rather than laparoscopy to assess 
for pelvic endometriosis preoperatively and diagnose pelvic adhesions 
postoperatively. Although a second look laparoscopy is commonly perceived by 
many as a gold standard to assess for the presence of pelvic adhesions or 
endometriosis, numerous studies have shown significant intra- and 
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interobserver variability, which is likely to be as operator dependent as non-
invasive diagnostic methods. 
Bowman et al.199 investigated the reproducibility of laparoscopy in assessing for 
pelvic adhesions by using video records of 25 women with pelvic adhesions. 
The recordings were reviewed by two assessors experienced in tubal surgery. 
They found a large variation in adhesion scoring between the assessors and 
poor agreement with endometriosis staging using the ASRM criteria.  
In a study by Hornstein et al.,93 five independent observers reviewed video 
recordings of 20 laparoscopies in patients with endometriosis and scored them 
according to the ASRM criteria. They also found a poor level of agreement 
between the observers in the classification of endometriosis of the ovary, cul-
de-sac obliteration and ovarian adhesions.  
Similar findings were reported in more recent studies. Weijenborg et al.200 found 
only a fair to moderate level of agreement in the intra- and interobserver 
assessment of ovarian adhesions when 90 video laparoscopic recordings were 
reviewed by two observers.  
All these studies indicate that there is a significant variation between the 
observers in the assessment of severity of endometriosis and assessment of 
ovarian adhesions when laparoscopy was used as the primary diagnostic tool. 
In addition, laparoscopy is costly and carries a significant risk of complication 
particularly when used to assess the efficacy of previous surgical treatment of 
endometriosis. In view of this, we decided that ultrasound may be a more 
appropriate tool to diagnosis endometriosis preoperatively and to assess 
women following surgery.  
Ultrasound had not been routinely used for the diagnosis of pelvic 
endometriosis in the past due to concerns about possible lack of sensitivity for 
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the detection of deep infiltrating endometriosis and pelvic adhesions201. 
However, recent studies have shown that continuing improvements in the 
quality of ultrasound equipment and development of novel examination 
technique have improved the accuracy and reproducibility of ultrasound 
diagnosis of pelvic endometriosis86,89. Furthermore, subsequent reproducibility 
studies found good levels of agreements between the operators for individual 
features of endometriosis including ovarian adhesions and pouch of Douglas 
obliteration177.  
Moore et al.83 systematically reviewed the validity of TVS for the detection of 
pelvic endometriosis and found sensitivities, speciﬁcities and positive (LR+) and 
negative likelihood ratios (LR−) in six studies ranged between 64 and 89%, 89 
and 100%, 7.6 and 29.8 and 0.1 and 0.4, respectively.  
As discussed in Chapter 7.5, Okaro et al.,178 found a high level of agreement 
(kappa, 0.80) between ovarian mobility on TVS and laparoscopy. Our results 
were slightly better when compared to Guerriero et al.179 who found only a 
moderate level of agreement (kappa, 0.51) in detection of ovarian adhesions. A 
more recent study by the same group assessed ovarian mobility by a 
combination of applying pressure between the uterus and ovary with the 
transvaginal probe and gentle abdominal palpation to assess for ovarian 
mobility180. They achieved much better accuracy with this technique which is 
very similar to our results.  
Reid et al.,202 assessed the reproducibility of TVS by recording the video TVS 
assessments of 30 women presenting with chronic pelvic pain and assessed for 
pouch of Douglas obliteration using the TVS ‘sliding sign technique’. Four 
ultrasound operators demonstrated near-perfect inter- and intraobserver 
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correlation. Diagnostic accuracy using this technique was sensitivity 93–100%, 
specificity 91–100%, PPV of 78–100% and NPV of 98–100%.  
TVS has also been shown to be a highly accurate and reproducible for the 
diagnosis of DIE in expert hands203,204. Hudelist et al.86 conducted a meta-
analysis and found the sensitivity and speciﬁcity of TVS in detecting 
rectosigmoid endometriosis to be 91% and 98%, respectively. A systematic 
review found that enhanced TVS (deﬁned as TVS with additional free ﬂuid, 
saline, water or gel in the rectum or vagina) did not improve the diagnostic 
accuracy of rectosigmoid DIE204.  A similar systematic review on the overall 
diagnostic performance of TVS for detecting DIE in the uterosacral ligaments, 
rectovaginal septum, vagina and bladder concluded that TVS had high 
specificities for the diagnosis of DIE at these sites. 
Savelli et al.,205 evaluated 69 women with TVS and double-contrast barium 
enema (DCBE) to predict posterior compartment DIE preoperatively. With 
regard to the prediction of bowel DIE, TVS vs DCBE gave accuracy of 91% vs 
45%, sensitivity of 91% vs 43%, specificity of 100% vs 100%, PPV of 100% vs 
100% and NPV of 29% vs 6%. They concluded that the sensitivity of 
transvaginal scanning is superior to DCBE and should be used as the method 
of choice for diagnosing bowel endometriosis.  
A recent Cochrane review found that MRI interobserver agreement was variable 
and a low intraobserver agreement was noted in non-expert MRI observers206. 
A meta-analysis evaluated the overall diagnosis of DIE using MRI found a 
sensitivity and specificity of 83% and 90%, respectively207. These results are 
comparable to TVS but there was no data on the accuracy of MRI for detecting 
pelvic adhesions. 
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The results of all these studies support our decision to utilise TVS rather than 
laparoscopy for the assessment of endometriosis and pelvic adhesions. It is 
reassuring that the rate of postoperative adhesions in our study was similar to 
the previous studies which used second-look laparoscopy to diagnose pelvic 
adhesions187.  
Our power calculation was based on a 50% reduction in the observed 60% 
postoperative adhesion rate in women without ovarian suspension after 
laparoscopic surgery for severe endometriosis. Some researchers may consider 
a 20% reduction to be clinically significant. However, we felt that a 50% 
reduction was required to justify the additional hospital stay and the risk of 
complications following ovarian suspension. Furthermore, a study adequately 
powered to assess for a 20% reduction would require a sample size of 390 
participants, based on a sample size calculation from Machin et al.,190 which 
could only be achieved in a large multicentre trial. Recruitment of patients in our 
study took longer than expected. This was due to a higher than expected rate of 
open surgery, excision of bowel disease and two stage surgeries. This resulted 
in the overall recruitment rate of 43% of women with found to have evidence of 
severe endometriosis on preoperative ultrasound. Despite the increased 
duration of the trial, the quality of our study was not affected as the surgical 
treatment and ovarian suspension was completed by the same surgical team 
throughout the duration of the trial. 
It is possible that ovarian suspension may be beneficial for women with less 
severe endometriosis. In our study, the majority of women had unusually severe 
endometriosis; 43 (82.7%) had complete obliteration of pouch of Douglas, eight 
(15.4%) had partial obliteration and 45 (86.5%) had DIE. Temporary ovarian 
suspension alone may never have been sufficient in this group of patients to 
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reduce the postoperative ovarian adherence and ovarian suspension in cases 
of ovarian cystectomies for endometriomas alone may produce a statistically 
significant result.  
Although, we did not find a statistical significant result in outcome, some would 
argue that the magnitude of effect matters more for clinical relevance than p-
values. With an odds reduction of 0.56 for ovarian adhesions with ovarian 
suspension, these findings may be meaningful. However, others could say that 
the lack of statistical significance, coupled with publication bias for small 
studies, would argue against utilisation.  
We found a significant improvement in women’s pain scores following surgery 
despite the relatively high prevalence of postoperative pelvic adhesions. 
Although the proportion of women complaining of pelvic pain was significantly 
less postoperatively, half of women continued to experience some pain, which 
was moderate to severe in 19.3% of them. In addition, 13.5% of women 
continued to complain of deep dyspareunia. This occurred despite successful 
and complete excision of all endometriotic lesions at laparoscopy. In view of 
these results, it is possible that postoperative pelvic adhesions are at least 
partly responsible for the persistent pelvic pain following laparoscopy for 
endometriosis. Postoperatively, 31 women (59.6%) were taking hormonal 
therapy compared to 14 (27%) women preoperatively. It is therefore possible 
that postoperative pain scores could have been worse if the proportion of 
women on hormone treatment was the same before and after surgery. 
Statistical comparisons were made between the 31 women who had hormonal 
treatment postoperatively and the 21 women who did not receive any hormonal 
treatment, but we found no difference in the adhesion rates between the two 
groups. Further analysis of the treatment groups and types of hormonal 
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treatment used did not suggest any difference. There was no suggestion in the 
literature that hormonal treatment has any effect on the formation of adhesions 
and our results would support this. However, the number of patients evaluated 
was small and our study was not sufficiently powered to evaluate this effect. A 
larger study will be necessary to further evaluate these effect.  
Ovarian cystectomies were performed on 61.6% of the participants. One would 
assume that the rate of adhesions would be naturally be higher when an 
ovarian cystectomy was performed on the same side. In our group of patients, 
we did not find this association. Again, this may be explained by our small 
number of patients and the severity of endometriosis in our patient group. 
Chapter 12 - Conclusion and further research 
This thesis has explored the complex pathology of endometriosis and 
highlighted a common problem of postoperative adhesions associated with the 
surgical treatment of this condition. I have described the detailed journey of an 
RCT from its conception, protocol design, pilot study, trial management, 
analysis to publication of results. In agreement with previous publications we 
found TVS to be an accurate tool in the diagnosis of features of pelvic 
endometriosis and diagnosis of pelvic adhesions.  
We found that temporary ovarian suspension for 36 to 48 hours in the 
postoperative period did not produce a statistically significant reduction in the 
prevalence of ovarian adhesion. This finding however, relates to patients with 
severe (stage 4) pelvic endometriosis. Further studies should be considered to 
evaluate the role of temporary ovarian suspension in women having surgery for 
mild to moderate endometriosis.  
We opted for shorter length of suspension because we were concerned about 
the risks with discharging patients home with sutures in situ. We recorded no 
complications related to the ovarian suspension. Future studies should explore 
whether longer ovarian suspension may result in significant reduction of 
postoperative ovarian adhesion. However, prolonged suspension could 
increase the risk of serious complication which could offset possible benefits of 
reduced prevalence of adhesions.  
Arguments against the use of TVS for the diagnosis of ovarian adhesions have 
centred on a perceived lack of accuracy with ultrasound and the regard of 
laparoscopy being the gold standard for diagnosis. Our findings and recent 
publications have strengthened the case for the use of TVS as a diagnostic tool 
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for features of endometriosis and adhesions without the need of second look 
laparoscopies.  
We found the prevalence of ovarian adhesion after laparoscopic surgery for 
severe endometriosis to be 56.3%. We found a significant improvement in 
women’s pain scores following surgery despite the relatively high prevalence of 
postoperative pelvic adhesions. Although the proportion of women complaining 
of pelvic pain was significantly less postoperatively, half of women continued to 
experience some pain, which was moderate to severe in 19.3% of them. Further 
studies to assess the prevalence of adhesions in varying severity of 
endometriosis may improve our understanding of the effects of adhesion on 
symptoms. Larger and longer term studies are also required to assess the long-
term impact of adhesions on clinical symptoms and fertility.  
We did not find a significant difference in the adhesion rates between women 
who used hormonal treatment postoperatively and those who did not. A larger 
study will be necessary to evaluate for the effects of hormonal treatment on the 
prevalence of adhesions.   
  137 
Chapter 13 – Contributions by Candidate 
The contributions by the candidate has been listed below: 
• Pilot Study 
o Design 
o Approval 
o Recruitment 
o All postoperative TVS scanning 
o Data collection & interpretation  
• Main RCT – Principal Investigator 
o Trial planning 
o Study protocol development 
o Liaising with statistics department 
o Ethics approval 
o Research and development consultations 
o Trial registration 
o Substantial amendments to trial protocols 
o Trial management and monitoring 
▪ Patient recruitment and consent 
▪ 64.7% of preoperative scans were completed by candidate 
▪ 63.5% of postoperative scans were completed by candidate 
▪ Data management & collection 
o Reporting of complication 
o Interpretation and publications of results 
• Statistical contributions 
o All statistical work and interpretation in this thesis have been 
completed by the candidate except for the power calculation, 
randomisation schedule, analysis of RCT primary outcome (Section 
11.4) and severity of ovarian adhesion (Section 11.5.1). 
o List of statistical analysis performed by candidate were Cohen’s 
kappa agreement, Chi square/ Fisher’s exact test, sensitivity, 
specificity, positive/ negative predictive value, positive/ negative 
likelihood ratio, area under receiver-operating characteristic curve, 
McNemar test and multilevel logistic regression. 
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Appendix 1 – Trial protocol from original 2003 study 
Study Protocol (Version 1) 
 
Does suspending the ovaries to the anterior abdominal wall reduce the incidence 
of adhesions found at the second look laparoscopy for endometriosis? 
 
Endometriosis is a common condition causing significant morbidity in women. It is often 
treated with laparoscopic surgery. Initially, at the first laparoscopy the adhesions are 
divided, the ovaries freed and the endometriotic cysts treated. The patients are then 
treated with GnRH analogues, which suppress the ovaries and reduce the activity of 
the endometriotic tissue. 3 months after treatment a second laparoscopy is performed 
to excise the remainder of the endometriosis, aided by the previous months of medical 
treatment.  We will have slots allocated to these patients on our operating lists in order 
to ensure a second operation at 3 months. 
We have found that at the second operation the ovaries have often become involved 
with adhesions again. We propose that by suspending the ovaries to the anterior 
abdominal wall the incidence of ovarian adhesions will be significantly reduced and 
thus the second laparoscopy will be less involved and the patient will be 
symptomatically improved. 
In order to see if there is a benefit in suspending the ovaries we propose the following 
study: 
For patients included in the study, at the end of their first laparoscopic treatment to 
endometriosis both ovaries will be suspended to the anterior abdominal wall with a 
Prolene suture and the suture brought out onto the skin and tied on the skin surface. 
The primary operator who will then leave the theatre at the end of the procedure, will 
grade the endometriosis on the left and right sides of the pelvis. Randomly the suture 
holding either the most or least affected ovary will be cut allowing that ovary to fall back 
into the pelvis immediately after the operation so that the principal surgeon is unaware 
of which side was actually sutured.  A Prolene suture will be placed in the skin at the 
same site in order that the patient remains blinded to which ovary remains suspended. 
Both sutures are then cut on the third post–operative day prior to the patient going 
home. 
The patient will then receive 3 months of GnRH analogue (either Prostap or Zoladex). 
At the start of the second laparoscopy the principal surgeon will grade the level of 
adhesions around each ovary. 
These adhesions will be compared with the level of adhesions found at the initial 
laparoscopy and correlated to whether the ovary was suspended to the abdominal wall 
or not. Each patient will be asked to complete pain scores using a visual analogue 
scale after their first procedure in order to assess if the sutures are related to any 
increase in post-operative pain. 
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Summary: 
1) Information leaflet and consent in clinic likely to need a 2-stage procedure. 
2) In theatre  
a) Second procedure not required – NOT entered into study. 
b) Second procedure required– entered into study. 
3) Both ovaries suspended to anterior abdominal wall after endometriomas drained 
and adhesions divided. 
4) Principal surgeon grades severity of endometriosis and adhesion formation on each 
side of the pelvis.  Grading is recorded using the same criteria for each patient 
(namely the revised ASRM along with a written description and a diagram). 
5) Randomly one suture is cut from either the most or the least affected ovary after 
principal surgeon has left the operating theatre. 
6) A similar suture is placed in the skin at the same site. 
7) Patient fills in postoperative pain scores on day 3. 
8) Both sutures are cut prior to the patient going home on day 3. 
9) Patient treated with 3 months of GnRH analogue. 
10) Second laparoscopy performed.  Severity of adhesion formation on each side of the 
pelvis graded by principal surgeon and any remaining endometriosis treated 
surgically. 
 
Power calculation 
We have calculated that we need 20 patients in the study to detect a 60% vs. 30% 
difference in adhesion rate with an 80% power and a p value assumed to be 0.05. 
 
State the intended value of the project, giving necessary scientific background.   
This study intends to determine whether suspending the ovaries to the abdominal wall 
will reduce ovarian adhesion formation. This reduction may result in better pain control 
and higher fertility rates. 
 
What are the outcome measures? 
The primary outcome was the grade of ovarian adhesions with and without ovarian 
suspension.  
 
A secondary outcome measure is the difference in pain between the 2 sides of the 
abdomen in the first 3 post-op days i.e. relationship of pain scores to ovarian 
suspension. 
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Appendix 2a – Final RCT Protocol 
Study Protocol Version 3 (Date: 15/03/10) 
 
Randomised study into the benefit of temporarily suturing the ovaries to the 
abdominal wall (oophoropexy) at laparoscopy for treatment of pelvic 
endometriosis to reduce the incidence of postoperative ovarian adhesions. 
 
Short title: Effectiveness of ovarian suspension in preventing postoperative ovarian 
adhesions in women with pelvic endometriosis.  
 
Endometriosis is a common benign condition, which causes a significant morbidity in 
the population of women of reproductive age. Severe pelvic endometriosis includes the 
presence of bilateral pelvic side wall and/ or rectovaginal disease. The most effective 
treatment of severe endometriosis is surgical excision of the disease, which is performed 
using keyhole surgery (laparoscopy). At the operation, the disease is usually excised 
completely, however, in a number of women the ovaries become stuck because of 
postoperative adhesions. 
We hypothesise that by suspending the ovaries to the anterior abdominal wall for at 
least 36 hours following surgery, we would be able to significantly decrease the 
incidence of postoperative ovarian adhesions, thus providing more effective treatment 
of pelvic pain and better reproductive outcomes.  
In order to see if there is a benefit in suspending the ovaries we propose the following 
study: 
All patients with suspected pelvic endometriosis would attend for a routine transvaginal 
ultrasound assessment prior to surgical treatment to assess the severity of their 
endometriosis. Women over the age of 18 with suspected bilateral pelvic endometriosis 
or endometriosis affecting the pouch of Douglas will be invited to participate in the 
study.  
During laparoscopic treatment for severe endometriosis, both ovaries are routinely 
suspended to the anterior abdominal wall using a Prolene suture, which is brought out 
onto the skin and secured using a fine haemostat or ‘mosquito’ clip during surgery. This 
is done to facilitate surgical excision of the disease and currently the sutures are 
removed at the end of the operation. The ovaries will then resume their normal 
anatomical position within the lesser pelvis. 
Women who are included in the ovarian suspension study will be randomised to have 
one ovary suspended for at least 36 hours. At the end of the operation, one suture will 
be released allowing that ovary to fall back into the pelvis. A new transabdominal suture 
will then be placed at the same site (contralateral to the suspended ovary). The air in the 
abdomen (pneumoperitoneum) will then be deflated and the Prolene stitch of the 
suspended ovary will be tightened with a surgical knot placed over the skin to secure the 
ovary to the abdominal wall. This will ensure that the suspended ovary is lifted as far 
away from the pelvis as possible. The surgical knot will be secured with the space of a 
Carless scissors between the skin and the surgical knot to allow easier removal of the 
suture and reduce patient discomfort. All randomised patients will therefore have two 
abdominal sutures of similar length and both the patient and ward staff will remain 
unbiased as to which ovary has been suspended. 
In the presence of ovarian cysts, there is no planned reconstruction of the ovary after 
excision of cyst (ovarian cystectomy). Healthy ovarian tissue will be opposed using the 
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same 2/0 Prolene stitch used for ovarian suspension and haemostasis achieved using 
diathermy.  
A sticker will be attached to the operation notes to define a) the randomization number 
b) the operation date and time and c) the earliest suture removal time (after 36 hours).  
There will be no documentation of the randomization site in the operation notes.  
Both sutures will be cut between 36 to 48 hours after surgery, prior to the patient being 
discharged home. Both sutures will be cut by a ward nurse who will not be part of the 
study and will not be aware of the ovarian suspension site. Instructions will be given to 
the surgeons and ward staff not to discuss possible ovarian suspension site with the 
patient after surgery or during the time of suture removal. 
In the event of postoperative pain or complication, both abdominal stitches will be cut. 
The time at which this is performed will be documented in the patient’s notes. If the 
ovarian suspension was performed for less than 36 hours, the patient will be excluded 
from the study.  
Three months after their operation, all patients participating in the study will be invited 
for a transvaginal ultrasound scan to assess the mobility of the ovaries. Adhesions will 
be diagnosed in women with evidence of restricted ovarian mobility on targeted 
palpation using transvaginal ultrasound probe. The ultrasound operators will be blinded 
to the details of the operative procedure and the site of temporary postoperative ovarian 
suspension. 
Statistical Considerations 
Pauline Rogers and Caoimhe O’Sullivan were involved in the trial design. Caoimhe 
O’Sullivan calculated the original sample size calculations in September 2003 and 
Pauline Rogers revised these when the protocol was amended in 2009. 
1) Sample size calculation 
Women with bilateral endometriosis will receive the normal surgical treatment with 
the difference that one ovary will be randomised to suspension and the other to non-
suspension.  The primary outcome is the binary variable of the presence of ovarian 
adhesions three months after surgery. 
The data is paired binary data.  The sample size calculation assumes that three 
months after surgery 60% of the non-suspended ovaries will exhibit ovarian 
adhesions and 30% of the suspended ovaries will exhibit ovarian adhesions.  The 
calculation follows section 7.3 in ‘Sample Size Tables for Clinical Studies’ by 
David Machin, Michael J Campbell, Say Beng Tan, & Sze Heuy Tan, Wiley-
Blackwell, third edition 2009. The calculation assumes that the response to 
suspension is independent to the response to non-suspension.  In a pilot study on 
women undergoing bilateral surgery (unpublished internal data) the intra-class 
correlation coefficient for the presence of adhesions three months after surgery was 
calculated to be 0.52, so this assumption may not be true but may be considered 
reasonable for sample size calculation purposes (Machin page 69).  The software 
provided by Machin et al was used to calculate that 45 women would be required for 
the study, assuming two-sided 5% significance and 80% power.  If it is assumed that 
there is a 10% dropout over three months, then 50 patients should be recruited to the 
study.  
36 women had the procedure in a period of 15 months (internal unpublished data): 
on average 2.4 procedures were carried out per month.  Assuming 2.4 women have 
the procedure per month it will take 21 months to recruit 50 women to the study.  
Allowing for the 3 months follow up period, data collection will take two years.  
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2) Statistical analysis 
a) The background characteristics of patients recruited to the trial will be described 
with means and standard deviations (or medians and inter-quartile ranges) for 
continuous variables and frequency counts and percentages for categorical variables. 
The background characteristics of the patients are: age in years, use of hormonal 
contraception (0 = no hormonal treatment, 1 = hormonal treatment) and pre-
operative ultrasound assessment endometriosis score (0 = disease absent [score = 0], 
1 = minimal disease [score = 1-5], 2 = mild disease [score = 6-15], 3 = moderate 
disease [score = 16-40] and 4 = severe disease [score = >40]). 
b) A CONSORT diagram will be produced to show the flow of patients through the 
study (Figure 7). 
c) The primary outcome, presence of ovarian adhesions, three months after surgery, 
was recorded for each ovary and analysed with a McNemar test.  Statistical 
significance will be declared at the 5% level.  The difference between suspended 
and unsuspended ovaries in the percentage with adhesions will be reported with 
95% confidence limits. 
d) Analysis of the secondary outcomes: 
i. The variable, adhesion score, will be analysed in a secondary analysis.  The 
score ranges from 0 (no adhesions) to 3 (fixed ovaries).  The adhesion score will 
be recorded for each ovary and the difference between the suspended and 
unsuspended ovaries was analysed with a McNemar test.  A statistically 
significant result would only be confirmed in an independent fully powered 
study.  The data from this study could be used for sample size calculations for 
future studies. 
ii. The presence and intensity of postoperative pain, will be measured using the 
visual analogue scale, where 0 = no pain and 10 = severe pain, will be 
summarised with frequency counts and percentages.   
e) The frequency and percentage of missing data will be reported for each variable. 
f) The frequency and percentage of patients who do not comply with the study 
protocol will be reported.  The reasons for non-compliance will be listed. 
g) The time point, frequency and percentage of patient withdrawals will be reported.  
The reasons for withdrawal will be listed. 
h) There were no plans for interim analyses. 
i) An independent statistician will carry out the final statistical analysis once trial 
follow up was complete.  
Randomisation: 
Subjects will be randomised to two equal groups, one group will have the left ovary 
suspended and the other group will have the right ovary suspended. Block 
randomisation will be used with three varying block sizes of minimum size 4.   
The randomisation schedule will be produced by our statistician Pauline Rogers using 
the external Stata command ralloc. The randomisation schedule and instructions for 
producing the randomisation envelopes will be handed to Sian Saw in a sealed 
envelope.  Sian Saw is completely independent from the trial team who will be 
recruiting to the trial.   
When a patient is recruited to the trial, consecutive randomization envelope will be 
opened and the principal surgeon will be told which ovary to suspend. Only the 
patient’s randomization number will be recorded in the patient’s operation notes. The 
principal surgeon will not inform the study team or clinical team responsible for the 
postoperative care or the patient of which ovary has been suspended.   
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At the end of the study, the randomization will be unblinded for analysis and details of 
the ovarian suspension will be added to each patient’s record. A copy of the 
randomisation schedule will be kept by Pauline Rogers on her computer in her personal 
area.  A second copy of the randomisation schedule will be kept with the sister in charge 
of ward T13 in a sealed envelope, in case of the need for emergency unblinding. 
Unblinding will only take place on instruction from the principal investigator or his 
appointed deputy. 
Summary of study protocol: 
1) Preoperative transvaginal ultrasound scan is routinely performed to assess the 
severity of endometriosis.  
2) Women with ultrasound features suggestive of severe endometriosis will be given 
an information leaflet and consented for the study.  
3) In theatre: 
• Principal surgeon grades severity of endometriosis and adhesion using the 
revised American Fertility Society Scoring System for Endometriosis. 
• Patients will have laparoscopic treatment for endometriosis which includes a 
routine oophoropexy. The Prolene stitch used for suspension will secured using 
a fine haemostat or "mosquito" clip during surgery.  
• In the presence of ovarian cysts: 
o No planned reconstruction of the ovary.  
o Healthy ovarian tissue will be opposed using the same 2/0 Prolene stitch 
used for the ovarian suspension.  
o Haemostasis will be achieved with diathermy.  
4) Randomization: 
• Only patients with severe endometriosis will be entered into study.  
• After complete laparoscopic treatment, patients included in the study will be 
randomised to have only one ovary suspended for at least 36 hours.  
• Consecutive randomization envelopes will be opened to obtain the ovarian 
suspension instruction. The suture holding the contralateral ovary is cut and the 
ovary is allowed to fall back into the pelvis. A new transabdominal suture will 
be placed at the same site.  
• At the end of surgery, the air in the abdomen (pneumoperitoneum) will be 
deflated. The Prolene stitch is tightened and a surgical knot is placed over the 
skin to secure the ovary to the abdominal wall. The same surgical knot is placed 
over the skin on the contralateral site. This will ensure that the suspended ovary 
is lifted as far as possible away from the pelvis as possible.  
• The surgical knot will be secured with the space of a Carless scissors between 
the skin and the surgical knot. This is to allow easier removal of the suture and 
reduce patient discomfort. 
• This will ensure that each patient will have two abdominal sutures that are 
similar in length and remain unbiased as to which ovary was suspended. 
• A sticker will be attached to the operation notes  
• No documentation of the randomization site in the operation notes.  
5) Ovaries will be suspended for at least 36 hours and up to 48 hours. 
• A ward nurse who will not be part of the study and will not be aware of the 
suspension site will cut both sutures. 
• Instructions will be given not to discuss possible suspension site with the patient 
after surgery or during the time of suture removal. 
6) Abandoning of suspension: 
• In the event of postoperative pain or complication, both abdominal stitches will 
be cut. The time at which this is performed will be documented in the patient’s 
notes.  
• If the ovarian suspension was performed for less than 36 hours, the patient will 
be excluded from the trial. 
7) Three months after operation, a transvaginal ultrasound scan is performed to 
examine for the presence of adhesions by assessing the mobility of the ovaries.  
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Appendix 2b – Patient Information Sheets and Consent Form 
 
 
Patient Information Sheet  
 
Title: Effectiveness of ovarian suspension in preventing postoperative ovarian 
adhesions in women with endometriosis  
 
Researchers:   
Dr. W Hoo, Mr. E Saridogan, Mr. G Pandis, Mr. A Cutner and Mr. D Jurkovic. 
Department of Obs & Gynae, Elizabeth Garrett Anderson Wing,  
University College London Hospital, 235 Euston Road London, NW1 2BU. 
 
We suspect that you may have endometriosis and would like to invite you to help us in 
our research study. This information sheet will provide you with information about the 
reasons for us wishing to conduct this study and what would be expected of you should 
you decide to help us.  
 
Background: Endometriosis is a common gynaecological condition, which typically 
presents with pelvic pain and fertility problems. It is caused by tissues, which are 
similar to the lining of the womb growing inside women’s pelvis. This usually affects 
the ovaries, bowel and the thin membrane covering the pelvic organs. Endometriosis 
can lead to the formation of ovarian cysts and extensive scarring within the pelvis, 
which causes pelvic pain. Severe endometriosis is most effectively treated using 
keyhole surgery. During operation, endometriosis tissue is excised and scarring is 
cleared to free the ovaries and other pelvic organs from the disease. However, following 
successful excision of endometriosis, women may still experience pelvic pain because 
the ovaries sometimes become stuck to the bottom of the pelvis due to postoperative 
scarring.  
 
What does the study involve? A surgical technique to reduce the chance of ovaries 
being stuck to the scar tissue has been proposed. This technique involves suspending the 
ovaries to the abdominal wall for at least 36 hours after the operation to clear 
endometriosis. We do not know how effective this technique is and this is the reason 
why we are conducting this study. In order to find the answer to this question, we are 
planning to keep one ovary stitched to the abdominal wall for 36 to 48 hours after the 
operation, whilst the other ovary would be allowed to fall back into the pelvis. By 
performing an ultrasound scan three months after the operation, we will try to find out 
whether the ovary, which was stitched to the abdominal wall, is less likely to be stuck to 
the bottom of the pelvis.  
 
Who can take part in the study? We will only invite women over the age of 18 years 
of age with confirmed diagnosis of severe endometriosis (affecting both ovaries and/or 
pouch of Douglas) to help us with this study.  
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Do I have to take part in the study? It is up to you to decide whether or not to 
participate. If you do decide to take part, you will be given this information leaflet to 
keep and asked to sign a consent form. If you decide to take part you are still free to 
withdraw from the study at any time. A decision to withdraw will not affect your future 
medical care.  
 
What will happen if I take part? You will have an ultrasound scan and be booked for 
the operation as normal. If diagnosis of severe endometriosis is confirmed at surgery, 
your ovaries would routinely be suspended to the anterior abdominal wall to facilitate 
removal of disease. Once the operation is completed, one of the ovaries will be let free 
while the other ovary will be kept suspended for 36 to 48 hours. You will not be able to 
tell which ovary is suspended as we will leave stitches on both sides of the abdomen. 
Both stitches will be cut before you go home. 
 
Three months after the operation, you will be offered an ultrasound scan during your 
routine postoperative review to determine whether your ovaries are stuck with 
adhesions.  
 
What are the risks of the study? This study will not in any way interfere with your 
treatment of your endometriosis or postoperative care. Suspending an ovary for 36 
hours is in addition to the usual operation and may add benefit in terms of long-term 
outcome.  There are no known additional risks involved as a result of this procedure. 
There may be a very small chance that adhesions may form around the suspended ovary 
although this has not been our experience to date. 
 
Will my taking part in this study be kept confidential? All information collected 
about you during the research will be kept strictly confidential and anonymous.  
 
What will happen to the results of the research study? The results will be analysed, 
presented in scientific meetings and published in peer reviewed journals. Your identity 
will not be revealed in any report or publications.  
 
The local Research Ethics Committee has reviewed this study and given its approval. 
 
For further information, please contact Dr William Hoo at the Gynaecology Diagnostic 
and Outpatient Treatment Unit, Level -1 (Clinic 3) Elizabeth Garrett Anderson Wing, 
University College London Hospital, 235 Euston Road, London NW1 2BU.  
Tel: 0207 380 9411 or Fax 0207 691 5861.  
 
Thank you for your time and consideration. 
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Study: Effectiveness of ovarian suspension in preventing postoperative ovarian 
adhesions in women with endometriosis. 
 
Patient Identification:  
 
 
 
CONSENT FORM 
Please tick box         
  
1) I confirm that I have read and understood the information sheet for the 
above study and I have had the opportunity to ask questions. 
2) I confirm that I have had sufficient time to consider whether or not you want 
to be included in the study. 
3) I understand that this is in addition to my usual procedures of treatment and 
that my participation is voluntary. I have the right to withdraw from the study 
at any time without giving any reason and without my medical care or legal 
rights being affected. 
4) I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals from 
UCLH, from regulatory authorities, from the NHS Trust or representatives of 
the sponsor for purposes of monitoring and auditing, where it is relevant to 
my taking part in this research.  I give permission for these individuals to 
have access to my records. 
5) I agree to take part in the above study. 
 
 
 
 
_________________________ ________________________       _____________ 
                Patient name        Signature       Date  
 
 
 
 
_________________________ ________________________       _____________ 
          Person taking Consent        Signature       Date  
 
 
Researcher to be contacted if there are any problems: Dr William Hoo 
 
Comments or concerns during the study: 
If you have any comments or concerns you may discuss these with the investigator. If 
you wish to go further and complain about any aspect of the way you have been 
approached or treated during the course of the study, you should write or get in touch 
with the Complaints Manager, UCL hospitals.  Please quote the UCLH project number 
at the top this consent form. 
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Appendix 2c - Ethical Approval for Substantial Amendment  
The Joint UCL/UCLH Committees on the Ethics of Human Research  
(Committee A) 
ICH Research & Development Directorate Office,  
1st Floor, 3 Long Yard, London, WC1N 3LU 
POSTAL ADDRESS:  
R&D Department, Institute of Child Health,  
30 Guilford Street, London,  
WC1N 1EH. 
Telephone: 0207 599 4144 
0207 905 2705 
Fax:  0207 599 4138 
a.mittu@ich.ucl.ac.uk 
 
 
09A 180 
 
08 April 2009 
 
Mr Ertan Saridogan 
Elizabeth Garrett Anderson Wing 
University College London Hospital 
235 Euston Road 
London NW1 2BU 
 
Dear Mr Saridogan 
 
Study title: Effectiveness of ovarian suspension in preventing post-
operative ovarian adhesions in women with 
endometriosis – Mr Ertan Saridogan 
REC reference: 003/0279 
Amendment date: 6 March 2009 
 
Thank you for submitting the above amendment, which was received on 10 March 
2009.  The amendment was considered at the meeting of the Sub-Committee of the REC 
held on 02 April 2009.   
 
Ethical opinion 
 
I am pleased to confirm that the Committee has given a favourable ethical opinion of 
the modified amendment on the basis described in the notice of amendment form and 
supporting documentation. 
Please note your patient information sheet is dated 4 Feb 2008 although in the list of 
submitted documents it is listed as 2009, I have made this change in pen (I assume this 
was an oversight) please change this in your version.  Also version numbers and dates 
are not listed on the consent form although I believe the intention is to submit as a 
combined document, please add these on the consent forms also. 
 
Approved Documents 
 
The documents reviewed and approved are: 
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Document Version Date 
Protocol  2 4 February 2009 
Participant Information Sheet & Consent 2 4 February 2009 
Notice of Substantial Amendment  1 6 March 2009 
   
Membership of the Committee 
 
The members of the Committee who were present at the meeting were Prof Raymond 
MacAllister and Dr Robert Urquhart. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it affects 
R&D approval of the research. 
 
Statement of Compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
003/0279:                 Please quote this number on all correspondence 
 
Yours sincerely 
 
A Mittu 
Committee Co-ordinator 
 
 
Appendix 3 – Trial Preparations 
3.1 Regulations 
Clinical trials in the UK are regulated by The Medicines for Human Use (Clinical 
Trials) Regulations 2004. These regulations implement the European Directive 
2001/20/EC ('The Clinical Trials Directive'). Clinical trials of medicinal products 
in human subjects are termed, Clinical Trials of Investigational Medicinal 
Products (CTIMPs) and require authorisation of the Medicines and Healthcare 
Products Regulatory Agency (MHRA) in the UK. This authorisation is granted in 
the form of a clinical trial authorisation (CTA). As our trial did not involve the use 
of a ‘medicinal product’, we were exempted from this authorisation.  
All clinical trials in the United Kingdom have to be conducted in accordance with 
the principles of good clinical practice (GCP) to ensure that all trials are 
conducted with high standards and minimal risks to patient volunteers.  
A robust trial design is essential to ensure a successful outcome and will help 
ensure that all necessary practical requirements are identified early. The 
Clinical Trials Toolkit (http://www.ct-toolkit.ac.uk/) provides practical advice to all 
researchers in designing and conducting publicly funded clinical trials. An 
interactive route map is available which provides information on best practice 
and outlines the current legal and practical requirements for conducting clinical 
trials (Figure 12). Although primarily aimed at CTIMPs, non-CTIMPs 
researchers will find useful information and guidance to the trial environment. 
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Figure 11 Clinical trials toolkit route map  
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3.2 Sponsorship 
The Research Governance Framework requires all health-related research to 
have a formal sponsor. The sponsor is the individual or institution that takes 
responsibility for the initiation, management and finance of a study. A sponsor 
must ensure that a study meets the relevant standards and ensure that 
arrangements are put and kept in place for management, monitoring and 
reporting. Sponsors can formally delegate one or more of the elements of 
sponsorship to the chief investigator. Institutions are expected to review 
individual studies for sponsorship on a case-by-case basis, usually through a 
formal application process initiated by the chief investigator.  
Our study was undertaken at the University College London Hospital (UCLH), 
which acted as our sponsor. A formal application process was obtained via 
ethical review and registration with joint Research and Development (R&D) 
Office.  
3.3 Trial Management and Monitoring 
Appropriate planning before the trial and adequate oversight and monitoring 
during the trial will help ensure that trial subjects safety is maintained 
throughout the trial and that there is accurate reporting of results at its 
conclusion. The sponsor maintains responsibility for ensuring that robust trial 
management systems are put in place, although as mentioned previously, these 
management activities can be delegated to the Chief Investigator or contracted 
out to third parties.  
Trial monitoring is not a standardised activity that must be implemented in an 
identical way in all trials. The purpose of trial monitoring is to provide oversight 
during the conduct of a trial to give reassurance that the study protocol and 
procedures are being followed, that and legal/governance requirements are 
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being complied with, and that the critical data collected are reliable. The extent 
and nature of monitoring would normally be determined prior to the start of the 
trial and be re-assessed during the course of a trial. Clinical risk assessment 
may be used to determine the intensity and the focus of the monitoring activity, 
whilst the trial design would inform the methods used for monitoring. 
Documentation should be in place to describe all key processes, to ensure that 
those performing tasks have a clear plan of what, when and how trial activities 
are undertaken. 
Key details and responsibilities that should be described in trial management 
documentation include:  
1. The trial protocol  
2. Organisational structure, including relevant details of the identity and 
responsibilities of all involved (sponsor, chief investigator, trial management 
team, host institution as applicable).  
3. Details of care organisations, participating sites and investigators.  
4. Details of the relevant regulatory approvals (e.g. ethics committee, clinical 
trial authorisation)  
5. The name of the individual who should be the first point of contact in the 
event of questions about the conduct of the trial (e.g. for audit/inspection 
purposes).  
3.4 Trial Documentations 
GCP requires that all clinical trial information be recorded, handled and stored 
in such a way that it can be accurately reported, interpreted and verified. 
Essential documents are those, which enable both the conduct of the clinical 
trial and the quality of the data produced to be evaluated. Many essential 
documents are filed in a Trial Master File / Investigator Site File.   
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It should be clear who is responsible for overseeing the preparation of key trial 
documentation and details of the review and sign-off process. The procedure 
and responsibility for assessing the substantiality of amendments to key 
documents such as the regulatory approvals, the protocol and patient 
information documentation should be documented.  
As the principal investigator of our RCT, I was responsible for obtaining and 
maintaining all the essential documents required for the trial master file. 
3.5 Trial Master File (TMF) 
A TMF consists of essential documents by which both the conduct of a clinical 
trial and the quality of the data produced can be evaluated. The TMF should be 
commenced from the beginning of a trial and maintained throughout the course 
of the trial in a well-kept manner to facilitate the reconstruction of a trial’s 
conduct during the audit/inspection process. Throughout the trial, the TMF 
should be kept in a secure but accessible manner. In cases where sponsor 
responsibilities have been transferred to the investigator, the TMF and 
Investigator Site Files are often combined.  
The European Commission has produced a detailed guidance on the list of 
essential documents for CTIMP trials. For non-CTIMP research, it would be 
good practice to file any document that meets the definition of an essential 
document on this list, although sponsors and host organisations may provide 
specific guidance on this in their policies. A list of essential documents for 
CTIMP research at various trial stages include: 
▪ Before commencement of trial  
i. Investigator’s brochure with all relevant and current scientific 
information about the investigational product 
ii. Signed protocol and amendments 
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iii. Patient information including the informed trial consent form 
iv. Financial aspects of the trial 
v. Insurance statement (where required) 
vi. Signed agreement between investigators, institutions and 
sponsors 
vii. Dated, documented favourable opinion of Ethics Committee  
viii. Certificate(s) of analysis of investigational medical product(s)  
ix. Decoding procedures for blinded trials in cases of emergency 
x. Master randomisation list 
xi. Pre-Trial Monitoring Report to document site suitability  
xii. Trial Initiation Monitoring Report to document that trial 
procedures were reviewed with the investigator and the 
investigator’s trial staff 
▪ During the conduct of the trial 
i. Document updates including any revision of the protocol, 
informed consent forms or patient information 
ii. Curriculum vitae for new investigators and supporting trial 
staff to whom investigator tasks are delegated 
iii. Updates of medical/laboratory/technical procedures/tests 
including normal ranges for medical/ laboratory/ technical 
procedures included in the protocol 
iv. Certification or accreditation or established quality control 
and/or external quality assessment or other validation 
v. Documentation of the distribution of investigational medicinal 
products and trial related materials  
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vi. Certificate(s) of analysis for new batches of investigational 
products 
vii. Monitoring visit reports 
viii. Signed informed consent forms in accordance with GCP and 
protocol and dated prior to participation of each subject 
ix. Signed, dated and completed case report forms 
x. Notification by originating investigator to sponsor of serious 
adverse events and related reports 
xi. Notification by sponsor and/or investigator, where applicable, 
to regulatory authority and Ethics Committees of suspected 
unexpected serious adverse reactions and of other safety 
information 
xii. Notification by sponsor to investigators of safety information 
arising from clinical trials on medicinal products for human 
use’ 
xiii. Interim or annual reports to Ethics Committees and 
authorities 
xiv. Subject screening log to identify trial subjects who entered 
pre-trial screening to allow investigators and institutional 
identification of any trial subjects 
xv. Subject enrolment log to document the chronological 
enrolment of subjects by trial number 
xvi. Investigational medicinal product accountability at each site 
xvii. Signature sheet to document signatures and initials of all 
authorised personnel making entries or corrections to case 
report forms 
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▪ After trial completion  
o Investigational medicinal products accountability and 
destruction at each site 
o Completed subject identification code list to identification of 
all subjects enrolled in the trial in case follow-up is required 
o Audit certificate 
o Final trial close-out monitoring report 
o Treatment allocation and decoding documentation 
o Final report by investigator to Ethics Committees and 
regulatory authorities 
o Clinical study report to document results and interpretation of 
trial. 
3.6 Contracts and Financial Management  
The contractual framework and budget management should be clearly defined. 
In many circumstances this role is undertaken by the host institution.  
In our RCT, the contractual framework was undertaken by our host sponsor, 
UCLH NHS trust. 
3.7 Insurance and Indemnity Arrangements  
Arrangements for insurance and indemnity, including arrangements to address 
negligent harm to the participant and adverse consequences of the 
interventions or trial procedures that are not due to clinical negligence should be 
stated. Our RCT was covered by the NHS indemnity procedures.  
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3.8 Monitoring  
Compliance with GCP is often interpreted as requiring active site monitoring, 
however the extent and nature of monitoring should be based on the objective, 
design, complexity, size and endpoints of the trial. In general, there is usually a 
need for on-site monitoring, before, during and after the trial with particular 
emphasis given to consent, eligibility, documenting safety information and study 
endpoints. There is now a consensus towards a more flexible and targeted 
monitoring process.  
The ‘Risk-adapted Approaches to the Management of CTIMPs’ has been 
published to help sponsors undertake the process of risk assessment. This 
document outlines a scheme for defining the risks associated with each clinical 
trial by a simple IMP risk categorisation (Type A, B and C) based on marketing 
status and standard medical care. This monitoring was not required in our non-
IMP trial.  
3.8.1 Trial Oversight Committees  
The funding body or sponsor may specify particular oversight arrangements. 
Commonly employed oversight committees include, a Trial Management Group, 
Trial Steering Committee and Data Monitoring Committee.  
3.8.1.1 Trial Management Group (TMG) 
Most trials have a TMG. In a small trial such as ours, the Chief or Principal 
Investigator may perform the functions of the trial management group. The TMG 
should include individuals involved in day-to-day management of a trial, such as 
the Chief or Principal investigator, research nurse and statistician. This group 
should keep a close eye on all aspects of the conduct and progress of the trial. 
They need to ensure that the trial protocol is adhered to and take necessary 
actions to safeguard participants and the trial itself. Trials with increasing 
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complexity will require a more formal structure and in larger trials, a Trial 
Steering Committee is recommended.  
3.8.1.2 Trial Steering Committee (TSC) 
The role of a TSC is to provide overall supervision of a trial and to ensure that 
the trial conduct is in accordance with the principles of GCP and the relevant 
regulations. Formalised procedures should be in place directing its formation 
and membership as well as its agreed responsibilities. The TSC should approve 
the trial protocol, any protocol amendments and provide advice to investigators 
on all aspects of the trial. The TSC monitors the progress of a trial including the 
recruitment, data completeness, and losses to follow-up and ensures that there 
are no major deviations from the trial protocol. A TSC will usually have 
members who are independent of the investigators, as well as two other 
independent members.  
3.8.1.3 Data Monitoring Committee (DMC) 
The role of a DMC is to review the accruing trial data and to assess whether 
there are any safety issues that should be brought to the attention of the TSC or 
any ethical reasons why the trial should not continue. A DMC should be 
considered for every trial, although one may not always be necessary. The 
decision as to whether or not a DMC would be useful should be based on the 
potential risks and benefits to subjects associated with the trial and the trial 
design. In the course of a blinded trial, it is the only body that has access to 
unblinded data. The DMC should be independent of both the investigators and 
the funder/sponsor. It should report to the TSC (or TMG if there is no TSC).  
Due to the small size of our trial, we decided against a DMC. The chief and 
principal investigators were responsible for the trial data and safety issues, 
whilst the statistician held the unblinded data. 
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3.9 Training  
Before a trial can begin, it is customary for an initiation meeting to be held to 
ensure that all trial staff are adequately trained and ready to start the trial. 
Investigator’s meetings, both before and during a trial, play an important role 
both in providing trial specific training, reviewing knowledge and understanding 
of trial procedures. Where training is required, the methods used to deliver 
training should be described with competency assessments detailed where 
necessary. The training delivered should be specific to their role and should be 
an on-going process. The trial team would also need to ensure that new staff 
joining the trial team receive the appropriate training before they undertake trial 
specific activities.  
The method of training and any on-going knowledge assessment will be 
influenced by the size of the group and geographical location of centres. For 
more complex trials where requirements differ markedly from routine care or 
where the use of novel procedures or specialised equipment are required, a site 
visit to each participating centre may be required to reassure the trial team that 
an adequate level of training has been achieved.  
In our trial, individual roles did not diverge from the routine care of a patient with 
severe endometriosis. The surgical team performing the ovarian suspension 
performed the procedure routinely to aid ovarian retraction during such cases. 
The ovarian suspension and placebo stitches were cut by a trained nurse 
before discharge. Trained research fellows and consultants performed the 
ultrasound assessments both before and after surgery. Both the chief and 
principal investigator attended a GCP course to familiarise ourselves with the 
basic principles of GCP. 
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Appendix 4 - Study Approvals  
4.1 Research and Development (R&D) Consultation 
Within NHS organisations, there are often R&D Departments or Clinical 
Research Offices. When organisations work closely together such as a local 
University and its local NHS Trust, as in the case of University College London, 
a joint R&D office is formed. These offices act on behalf of its organisation to 
facilitate the local management of all research within that organisation. They 
need to ensure that appropriate arrangements are put in place to support the 
research and that risk management measures including appropriate insurance 
and indemnity provision are in place.  
An R&D Office must give formal permission before a research project can take 
place within their organisation. When acting as the sponsor, NHS R&D offices 
will be involved in the oversight of the trial by guiding the Chief Investigator and 
managing the risks associated with any trial initiated. It is advisable to contact 
the local R&D Office in the early stages of study development so that they can 
help identify facilities that can provide valuable support. 
It will be important when consulting R&D to define how costs are allocated. A 
recent guidance has been published to provide a framework for the NHS and its 
partners to identify and attribute the costs of health and social care R&D in a 
transparent and consistent manner by differentiating between research costs, 
NHS service support costs and treatment costs in relation to activities specified 
in the protocol. 
4.2 Funding Proposal  
Securing funding can be a lengthy process, therefore the time required to 
secure funding should be included in the wider development and planning of 
trial activity. Funders will need to be assured that the proposed research is 
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important and addresses a clear need, well designed, feasible and scientifically 
valid, and offers value for money. The funding schemes will have varying 
eligibility requirements and many funders offer resources to enable researchers 
to confirm suitability ‘in principle’ at an early stage. 
In our small RCT, formal funding was not sought. However, the principal 
investigator (WH) was supported by the research fund provided by the 
Gynaecology Ultrasound Centre, UK.  
4.3 Peer Review 
Peer review is an opportunity for expert examination of the proposed trial to 
consider aspects including the design quality, feasibility, acceptability and 
importance of the topic. Experts in this context will include views from relevant 
clinicians, allied health professionals and other professional groups, patients 
and members of the public. Peer reviews will usually be undertaken as part of 
an external funding application process. However, if an external funding was not 
required, then the sponsoring organisation will be able to assist with this in the 
form of an ethical approval process. 
After completing our ethical approval, our trial protocol was published in a peer 
reviewed literature208.  This not only shores up the transparency of reporting of 
the trial results, but also allows critical comments from the scientific community 
at the design and initial phase of the trial.  
4.4 Unique Trial Number 
The registration of clinical trials is now advocated and each trial must have a 
unique trial number. Trial registration is regarded as the publication of an 
internationally agreed standard dataset about a clinical trial on a publicly 
accessible database managed by a registry conforming to the World Health 
Organization standards. This requirement is quoted in a number of publications 
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including the Declaration of Helsinki of the World Medical Association and the 
Research Governance Framework.  
From the 1st of July 2005, the International Committee of Medical Journal 
Editors has agreed that trial results will not be published unless the study has 
been included on a clinical trials registry. This is to allow a trial to be tracked 
from initial protocol through to publication.  
The International Standard Randomised Controlled Trial Number (ISRCTN) is a 
simple numeric identification system that can be used to track all publications 
and reports resulting from each trial. Alternatively, trials may be registered at 
clinicaltrials.gov. For CTIMPs, there is an additional mandatory reference, 
EudraCT number, allocated by the European Medicines Agency.  
In England, trials where all costs are met fully by an NHS Trust, there is an 
automated ISRCTN registration on the NHS Clinical Trial Register. Our trial 
reference is ISRCTN24242218. 
4.5 Confirm Sponsor 
For UK trials, the chief investigator will be required to approach a potential 
sponsor who will assess the operational risk of the proposed trial before 
confirming sponsorship.  For NHS sponsors, the NHS R&D office in their 
respective organization usually performs confirmation of sponsorship. 
Sponsorship will only be granted once issues raised by the risk assessment 
have been addressed. A letter confirming sponsorship must be retained in the 
Trial Master File.  
4.6 Feasibility Assessment 
Trials that fail to reach their study targets may not achieve a statistically 
significant result or require further funding. It is therefore worth considering a 
feasibility study or as in our case, a pilot study, ideally during the funding 
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process. This process may help identify possible barriers to the recruitment 
process or allow for an assessment of the expected recruitment rate.  
For larger multi-site trials, careful selection and evaluation of investigator sites is 
critical for the successful completion of a trial within budget, deadlines and to 
ensure the generation of high quality data. 
4.7 Final Protocol  
Before seeking approvals to start a trial, the protocol must be finalised and 
endorsed by the sponsor, chief investigator and trial statistician. The sponsor 
will usually specify the signatory requirements. In multi-site trials, it is good 
practice to ensure the Principal Investigator signs a protocol signature page to 
confirm receipt and also their agreement to work to the current version of the 
protocol. Our final protocol is illustrated in Appendix 2 including a new patient 
information leaflet and consent form (Appendix 3). 
4.8 IRAS (Integrated Research Application System) 
The IRAS is a single system for applying for the permissions and approvals for 
health and social care research in the UK. This includes applications for Ethics 
Approval, Clinical Trial Authorisation, R&D Management approval and ‘Notice of 
Substantial Amendment’. Users of the system will need to register for an IRAS 
account and there is a free e-learning module, which illustrates the system and 
its functionality. 
Completion of the project filter will enable the required permissions and 
approvals applications to be created for the specified project. Questions that are 
not relevant to the type of project will be disabled in the project dataset.  
4.9 Clinical Trial Authorisation (CTA) Submission 
CTIMP trials in the UK will require a CTA from the Medicine and Healthcare 
Products Regulatory Agency (MHRA). Prior to this application, each trial must 
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also be registered on the European Clinical Trials Database by obtaining a 
EudraCT number. Our non- CTIMP trial was exempted from this process.   
4.10 Ethics Submission 
A well-designed trial should answer important public health questions without 
impairing on the welfare of individuals. There may, at times, be conflicts 
between a physician’s perception of what is good for his or her patient and the 
design and the conduct of the trial. In such instances, the needs of the patient 
must predominate. The National Research Ethics Service (NRES) exists to 
protect the rights, safety, dignity and wellbeing of research participants whilst 
facilitating ethical research that is of potential benefit to participants, science 
and society. This is achieved through the review of research taking place within 
the NHS by NRES Research Ethics Committees (RECs). Application to NHS 
RECs should now be made using IRAS as described above. RECs will give 
their opinion about the proposed participant involvement and whether the 
research is ethical.  
Although the majority of research conducted within the NHS will require ethical 
review, some projects are more appropriately classified under clinical audit or 
service evaluation. If a researcher is unsure as to whether their project will 
require ethical approval, a Health Research Authority algorithm is available to 
help determine this. 
An ethics approval for ovarian suspension was approved for the original study 
2003. As there were no intended changes to the study population or 
intervention, we were advised following consultation with the ethics department 
to apply for a substantial amendment. A successful application was obtained for 
our substantial amendment in April 2009 (Appendix 2c).  
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4.11 Substantial Amendments 
Amendments are changes made to the research after review body approval has 
been given. Amendments requiring approval cannot be implemented until the 
relevant approvals are in place, except in the case of urgent safety measures. A 
substantial amendment is defined as an amendment to the terms of the 
application or protocol or any other supporting documentation, that is likely to 
affect to a significant degree the: 
o safety or physical or mental integrity of the trial participants 
o scientific value of the study 
o conduct or management of the study or 
o quality or safety of any IMPs used in the trial. 
It is the responsibility of the sponsor to determine whether an amendment is 
substantial or non-substantial.  For both CTIMPs and non-CTIMP research, 
‘Notice of Substantial Amendment’ forms can be created in IRAS. NHS R&D 
offices sponsoring research will need to be notified of all amendments so that 
they may assess for any impact on governance arrangements or resources.  
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Figure 12 Flowchart illustrating the process of ethical review of substantial 
amendments to approved research 
 
  
Chief Investigator (CI) submits 'NRES Notice of 
Substantial Amendment Form' and supporting 
documents to main REC for review 
REC co-ordinator validates amendments within 5 
working day. 
(Coordinator may decide amendment is minor)
Minor Amendment
Valid Notice of 
Amendment
Amendment review by Main 
REC or sub committee
Co-ordinator notifies CI of decision within 35 
days of receiving valid Notice of Amendment
Favourable Opinion Unfavourable Opinion
CI submits modified 
amendment
Co-ordinator to arrange for modified 
amendment to be reviewed by sub-
committee or Chair with decision within 14 
days of receiving modified amendment
Favourable Opinion
Unfavourable Opinion
Invalid Notice of 
Amendment
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4.12 R&D Submission 
Research conducted within NHS organisations must obtain permission from the 
R&D department of each organisation taking part in the trial. Without this 
approval in writing, indemnity and insurance cannot be assumed to be in place 
to cover the proposed research activity. The R&D permission process is two-
fold with general trial information captured in the NHS R&D form and local site 
information on the NHS Site-Specific Information (SSI) form. Each of the SSI 
forms will need to be completed separately with local information. NHS R&D 
offices assess the suitability of the local research site and investigator. 
Applications for NHS permission in England, Wales, Scotland and Northern 
Ireland should now be made using IRAS, which will include guidance on the 
completion and submission of the NHS R&D form and specific SSI forms. NHS 
permission will only be issued after all other approvals required for the trial have 
been granted. 
4.13 Permissions & Approvals Obtained 
A trial cannot begin until all the relevant permissions and approvals have been 
obtained and reviewed by the chief investigator and sponsor. Clear evidence of 
the documents submitted to the approval bodies and the approval letters need 
to be retained in the TMF. For multi-site trials, the Chief Investigator will ensure 
that each Principal Investigator is provided with all relevant, version-controlled 
documents before commencing recruitment. 
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Appendix 5 – Study Begins 
5.1 Trial Begins 
Trial commencement is often accomplished by holding a start-up meeting. This 
will allow the Chief Investigator to satisfy him or herself with all the technical 
aspects and to ensure that the protocol requirements are fully understood by all 
relevant site staff.  It is also a great opportunity to ask questions and clarify 
misunderstandings.  
Trial specific training, as well as training on aspects of trial conduct and safety 
reporting requirements are often undertaken at this stage. For CTIMPs, this 
communication should include a pharmacist, so that all requirements can be 
confirmed before dispensing IMPs.  
A start-up meeting was held in October 2009, prior to the commencement of our 
trial and was attended by all the investigators.  
5.2 Informed Consent 
With the exception of certain emergency trials involving incapacitated adults or 
minors, all participants must give their informed consent before being entered 
into a trial. For CTIMPs, Schedule 1 of The Medicines for Human Use (Clinical 
Trials) Regulations 2004 describes the requirements for consent. For non-
CTIMPs conducted in England and Wales, it is the Mental Capacity Act that 
regulates inclusion into research. This is to ensure that all UK trials are 
conducted to the appropriate high standard and that risks to patient volunteers 
are minimised.    
For each trial, specific consent documents consisting of a participant 
information sheet and consent form must be developed and approved by the 
ethics committee. The ethics committees usually encourage the involvement of 
patient groups in the development of these documentations. 
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It is imperative that informed consent is given freely, which may be challenging 
in trials involving complex interventions, potentially toxic treatments or invasive 
procedures. Training and competency assessment of investigators obtaining 
informed consent may be helpful to ensure that the trial is presented in a 
balanced manner. These techniques may reveal deficiencies in the level of 
understanding, style of presentation, or extent of discussion in the consent 
process. If training is required, all those who may request consent from subjects 
participating in the trial should be included. For simple or low risk trials, it is 
often sufficient to check that the consent form has been signed and dated and 
that there is a record of the information provided to subjects.  
Throughout the trial, the subject’s willingness to continue participation should be 
reaffirmed periodically. If significant new information becomes available during 
the course of the trial, participants will need to be provided with revised and re-
approved consent documentation so that written consent can be formally 
documented if the subject is willing to continue. 
5.3 Progress Reporting 
During the course of a trial, there is a requirement to send regular progress 
reports. The ethics committee, trial sponsor and R&D Offices where the trial is 
conducted usually require an annual report. This was completed yearly during 
the course of our trial. For CTIMPs, this progress report is in addition to an 
annual safety report.  
5.4 Trial Communication  
Details relating to the communication of key trial information should be in place. 
This should include the contents, frequency or timing and mode of 
communication used. Regular project meetings to review trial progress should 
be recorded so that all actions, key decisions and timelines are clear.  
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5.5 Good Clinical Practice (GCP) Inspections  
The MHRA are required under European law to inspect all CTIMPs. The 
sponsors themselves would evaluate the efficiency of their quality control by 
selecting a number of trials to review their compliance with their relevant 
legislation and guidance. GCP inspections will include an element of risk 
assessment within them and will consider the nature of the trial conducted, the 
extent and vulnerability to the population studied and any prior inspection 
history. Where possible, the focus is on more complex trials, although trials 
equivalent to standard care have been included to evaluate the system. 
Findings that could result an inspection varies from inadequate documentation 
to concerns regarding participant safety.  
We were not subjected to a GCP inspection during the course of our trial.  
5.6 GCP & Serious Breach Reporting  
The Research Governance Framework requires that all research are conducted 
in accordance with the principles of GCP. This is to ensure that the rights, 
safety and wellbeing of trial participants are protected. For CTIMPs, Part 5 of 
the Medicines for Human Use (Clinical Trials) Regulations SI 1031 (sections 32-
35) defines the responsibilities for safety reporting of both the sponsor and the 
investigational site. For non-CTIMP research, serious breaches of GCP or the 
protocol should be reported to the relevant ethics committee so implementation 
of corrective and preventative actions can be made. 
Any serious breach of the conditions and principles of GCP or the protocol 
relating to the trial will need to be reported. A “serious breach” is a breach that 
is likely to affect to a significant degree the safety or physical or mental integrity 
of the subjects of the trial, or the scientific value of the trial.  
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The judgement on whether a breach is likely to have a significant impact on the 
scientific value of the trial will vary depending on the design of the trial, the type 
and extent of the data affected and the overall contribution of the data to 
analysis. It is the responsibility of the sponsor to assess the impact of the 
breach on the scientific value of the trial and should be documented. 
Deviations from clinical trial protocols and GCP occur commonly in clinical trials. 
The majority of these instances are technical deviations that do not result in 
harm to the trial subjects or significantly affect the scientific value of the 
reported results of the trial. These cases should be documented in order for 
appropriate corrective and preventative actions to be taken. In addition, these 
deviations should be included and considered when the clinical study report is 
produced, as they may have an impact on the analysis of the data. The sponsor 
or responsible person should make notification of serious breaches within 7 
days of being aware of the breach.  
Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse 
Reactions (SUSARs) resulting from a breach of the conditions and principles of 
GCP or a breach of the protocol will constitute a serious breach. However, not 
every SAE or SUSAR would routinely be classified as a serious breach.  
5.7 Urgent Safety Measures 
The Clinical Trials Regulations make provision for the sponsor and investigator 
to take appropriate Urgent Safety Measures (USMs) to protect a research 
participant from an immediate hazard to their health and safety. This measure 
can be taken before seeking approval from the competent authorities including 
MHRA or ethics committees. 
The Chief Investigator must notify the main REC immediately of any USMs and 
in any event within three days. NHS R&D offices will also require notification in 
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accordance with local policies/procedures. Any USMs relating to a CTIMP must 
also be communicated to the MHRA immediately via telephone with a written 
notification within three days of the action being taken. The notification should 
be in the form of a substantial amendment and should describe the event, the 
measures taken and justification for the measures taken.  
There was no requirement to undertake a USM during our trial.  
5.8 End of Trial Declaration 
The definition of the end of the trial should be provided in the protocol. In most 
cases this will be the date of the last visit of the last patient undergoing the trial 
or the date of the final data capture where follow up monitoring is required.  
For CTIMP research, the Clinical Trials Regulations require the sponsor to 
notify the MHRA and ethics committees of the end of a trial within 90 days. A 
EudraCT Declaration of End of Trial Form should be completed. NHS R&D 
offices will also require notification in accordance with local policies/procedures. 
For non-CTIMP research, notification to the relevant ethics committee and R&D 
offices is required. The ‘NRES Declaration of the End of Trial Form’ should be 
used. This was done at the end of our trial. 
5.9 Statistical Data Analysis 
In the majority of trials, sponsors would require appropriate arrangements to be 
specified during the trial design phase and the services of an appropriately 
trained statistician to be secured. This is to ensure that the analyses to evaluate 
all planned study hypotheses are conducted in a scientifically valid manner and 
that all decisions are documented. Support for trial data management and 
statistical analysis is available from a range of sources including local R&D 
departments and UKCRC registered Clinical Trials Units. 
The statistical analysis should include the: 
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• Primary and key secondary outcome measures stated in the protocol  
• Methods for handling missing data and multiplicity of data 
• Justification for any non-standard statistical techniques 
• Details of any subsequent post hoc analysis to be justified and reported 
in any publication 
The trial results should be discussed with the Chief Investigator and other 
relevant oversight groups including the DMC, to assist interpretation and 
implications of the findings. Other important considerations include practicalities 
relating to the blinding of the trial statistician and documentations of all data 
manipulations and analyses performed on the original data to allow replication 
of analysis. After analysis, all relevant documentation in the possession of the 
statistician should be filed in the TMF. 
5.10 Clinical Trial Summary Report 
The investigators must provide a clinical trial summary report to the REC (and 
MHRA for CTIMPs) within 12 months of the end of the study. Although there is 
no standardized format for such reports, as a minimum, the report should 
include details of whether the trial achieved its objectives, main trial findings and 
arrangements for publication or dissemination of the research. For CTIMPs 
research, the final report should be formatted according to the ICH E3 guideline 
for structure and content.  
RCTs should be reported in compliance with the CONSORT Statement. This 
initiative was developed to improve the reporting of RCTs, enabling readers to 
understand a trial's design, conduct, analysis and interpretation, and to assess 
the validity of its results. Similar initiatives have been developed for other study 
designs, STARD for reporting diagnostic accuracy studies, STROBE for 
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reporting observational studies in epidemiology and PRISMA for reporting 
systematic reviews.  
5.11 Dissemination of Results 
It is important that the results of clinical research are disseminated to the 
research community, trial participants and general public. The most obvious 
route to inform the research community is through publication in peer-reviewed 
scientific journals.  
The dissemination of research findings promotes research participation and 
demonstrates that findings have improved current clinical practice. Informing 
participants of results acknowledges their contribution to the trial. It is important 
to establish whether a participant will want to be actively informed of trial 
results, or whether they would like the onus to be left with them to obtain the 
results. Organisations may also employ different other strategies for informing 
the public of their trial findings. This may include publication of trial results in 
open access journals, trust websites or employing the use of leaflets in hospital 
waiting rooms. It is good practice for investigators to check whether the NHS 
R&D offices that gave approval require a copy of any publications or reports. 
5.12 Conflict of interest 
A widely expressed concern in clinical research is the potential for conflict of 
interest on the part of the investigators. Ideally, no investigator would have any 
interests other than the wellbeing of the study participants and the generation of 
new knowledge, however, financial or intellectual conflicts may occur. In the 
ethical contest, conflict of interest can lead to bias in design, conduct, analysis, 
interpretation and communication of findings.  
Most investigators manage conflict of interest by disclosing financial 
relationships to participants, although it may not be fully apparent what impact 
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financial relationships might have on the research design, conduct and analysis. 
Any investigators with economic interests in the outcome should either not 
participate or not have opportunities to affect and publish the trial outcome. 
Completely openness and data analysis by an independent group is crucial. 
Ultimately, a clinical trial results must be believed and accepted by the clinical 
communities and if the extent of conflict of interest lessens that acceptance, 
then a study is impaired.  
Possible conflicts of interest in our study were declared in our publications. 
Ertan Saridogan received honoraria from Ethicon for provision of training to 
healthcare professionals and consultancy fees from Bayer. Alfred Cutner was 
on the advisory board for surgical innovations for which he received annual 
honorarium. He also received support for courses and education from Storz and 
Johnson and Johnson and support for clinical nursing from Covidien and Lotus. 
Other authors declared no competing interests.  
5.13 Archiving  
All study documentations including the TMF, case report forms and other 
essential documents must be archived. Consideration should be given for the 
archive of both paper and electronic data. For CTIMP research, the sponsor 
and chief investigator must ensure that the medical files of trial subjects are 
retained for at least 5 years after the conclusion of the trial. Clinical Trials 
Regulations require the sponsor to appoint ‘named individuals’ within its 
organisation to be responsible for archiving and setting up systems to track and 
retrieve archived documents. Named individuals should also ensure that archive 
facilities are secure with appropriate environmental control and adequate 
protection from physical damage. 
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For non-CTIMP research, the archive time period is usually stipulated by the 
local sponsor, although NHS Research Ethics Committees should retain all 
relevant records for a period of at least three years after completion of a 
research project.  
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Appendix 6a – Study Protocol- Effectiveness of ovarian suspension in 
preventing post-operative ovarian adhesions in women with pelvic 
endometriosis: A RCT 
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Appendix 6b - Does ovarian suspension following laparoscopic surgery for 
endometriosis reduce postoperative adhesions? An RCT. 
 
 
 
  
  208 
 
 
 
  
  209 
 
 
 
  
  210 
 
 
 
  
  211 
 
 
 
 
  
  212 
 
  
  213 
 
 
 
  
  214 
Appendix 6c - Reply: Criticizing the effect of ovarian suspension on adhesions in 
laparoscopic surgery for endometriosis. 
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Appendix 6d - Reply: ovarian suspension for longer than 36 h is necessary for 
temporary ovarian suspension to fulfil its remit. 
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